WO2023023397A1 - Methods for inhibiting the progression of neurodegenerative diseases - Google Patents
Methods for inhibiting the progression of neurodegenerative diseases Download PDFInfo
- Publication number
- WO2023023397A1 WO2023023397A1 PCT/US2022/041062 US2022041062W WO2023023397A1 WO 2023023397 A1 WO2023023397 A1 WO 2023023397A1 US 2022041062 W US2022041062 W US 2022041062W WO 2023023397 A1 WO2023023397 A1 WO 2023023397A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arachidonic acid
- dose
- ester
- disease
- deuterated
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 56
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 46
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 45
- 230000002401 inhibitory effect Effects 0.000 title abstract description 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 220
- 150000002148 esters Chemical class 0.000 claims abstract description 130
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 238000011068 loading method Methods 0.000 claims description 69
- 238000012423 maintenance Methods 0.000 claims description 58
- 206010061818 Disease progression Diseases 0.000 claims description 55
- 230000005750 disease progression Effects 0.000 claims description 55
- 230000001225 therapeutic effect Effects 0.000 claims description 34
- 239000002775 capsule Substances 0.000 claims description 25
- 230000000737 periodic effect Effects 0.000 claims description 22
- 210000002569 neuron Anatomy 0.000 claims description 20
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 15
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 14
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 230000003859 lipid peroxidation Effects 0.000 claims description 9
- 208000034799 Tauopathies Diseases 0.000 claims description 8
- 230000036961 partial effect Effects 0.000 claims description 8
- 230000000750 progressive effect Effects 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 206010033799 Paralysis Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000021090 palsy Diseases 0.000 claims description 4
- 208000001282 primary progressive aphasia Diseases 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 19
- 229940114079 arachidonic acid Drugs 0.000 description 107
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 52
- 235000021342 arachidonic acid Nutrition 0.000 description 49
- 210000003743 erythrocyte Anatomy 0.000 description 31
- 238000002560 therapeutic procedure Methods 0.000 description 29
- 230000009467 reduction Effects 0.000 description 26
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 14
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 235000020778 linoleic acid Nutrition 0.000 description 12
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 12
- 125000004494 ethyl ester group Chemical group 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 125000004431 deuterium atom Chemical group 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 210000002161 motor neuron Anatomy 0.000 description 10
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 9
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000008717 functional decline Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- OYHQOLUKZRVURQ-ZVDPVMROSA-N (9z,12z)-11,11-dideuteriooctadeca-9,12-dienoic acid Chemical compound CCCCC\C=C/C([2H])([2H])\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-ZVDPVMROSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 102000013498 tau Proteins Human genes 0.000 description 5
- 108010026424 tau Proteins Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960002733 gamolenic acid Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- -1 monoglycerides Chemical class 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 2
- 208000016270 Corticobasal syndrome Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000016871 Hexosaminidase A Human genes 0.000 description 2
- 108010053317 Hexosaminidase A Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000020176 deacylation Effects 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 208000017004 dementia pugilistica Diseases 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- SIRZPOBKMRMKDI-UHFFFAOYSA-O 10-(2,5-dihydroxy-3,4-dimethoxy-6-methylphenyl)decyl-triphenylphosphanium Chemical compound OC1=C(OC)C(OC)=C(O)C(C)=C1CCCCCCCCCC[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 SIRZPOBKMRMKDI-UHFFFAOYSA-O 0.000 description 1
- OIIMUKXVVLRCAF-UHFFFAOYSA-N 10-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium Chemical compound O=C1C(OC)=C(OC)C(=O)C(CCCCCCCCCC[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C OIIMUKXVVLRCAF-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- PQDRWMYDXMMMBP-UHFFFAOYSA-N 2-oxoicosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(=O)C(O)=O PQDRWMYDXMMMBP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000004066 Ganglioglioma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000036187 Genetic neurodegenerative disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 1
- 208000017463 Infantile neuroaxonal dystrophy Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 102100023410 Phospholipid hydroperoxide glutathione peroxidase Human genes 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000032561 Rare neurodegenerative disease Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 description 1
- 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- BKQFRNYHFIQEKN-UHFFFAOYSA-N erastin Chemical compound CCOC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C(C)N1CCN(C(=O)COC=2C=CC(Cl)=CC=2)CC1 BKQFRNYHFIQEKN-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005649 gangliocytoma Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030309 inherited neurodegenerative disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
Definitions
- the methods use a specific dosing regimen to treat patients suffering from a neurodegenerative disease treatable with a deuterated arachidonic acid or a prodrug thereof.
- the dosing regimen provides for rapid onset to a therapeutic concentration in vivo of deuterated arachidonic acid at a level where the progression of the disease is markedly reduced.
- neurodegenerative diseases there are a number of debilitating neurodegenerative diseases in humans which, despite the best efforts of researchers, remain incurable and often fatal. As such, the best the attending clinician can do is to slow the progression of the disease and, where possible, maintain a meaningful quality of life for the patient for as long as possible. Examples of such neurodegenerative diseases include the following:
- ALS amyotrophic lateral sclerosis
- tauopathy is a subgroup of Lewy body diseases or proteinopathies and comprises neurodegenerative conditions involving the aggregation of tau protein into insoluble tangles. These aggregates / tangles form from hyperphosphorylation of tau protein in the human brain.
- tauopathy include, but are not limited to, argyrophilic grain disease (AGD), chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), ganglioglioma, gangliocytoma, lipofuscinosis, lytico- bodig disease, meningioangiomatosis, pantothenate kinase-associated neurodegeneration (PKAN), Pick’s disease, postencephalitic parkinsonism, primary age-related tau op athy (PART), Steele-Richardson-Olszewski syndrome (SROS), and subacute sclerosing panencephalitis (SSPE).
- ALD argyrophilic grain disease
- CTE chronic traumatic encephalopathy
- CBD corticobasal degeneration
- FTDP-17 frontotemporal dementia and parkinsonism linked to chromosome 17
- ® Friedreich’ s ataxia is an autosomal-recessive genetic disease that causes difficulty walking, a loss of sensation in the arms and legs, and impaired speech that worsens over time.
- the pathology of this neurodegenerative disease involves degeneration of nerve tissue in the spinal cord;
- ® Huntington’s disease is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain
- Corticobasal disorder is a rare neurodegenerative disease characterized by
- CBD corticobasal syndrome
- Frontotemporal dementia is a neurodegenerative disease and a common cause of dementia. It is characterized by a group of disorders that occur when nerve cells in the frontal temporal lobes of the brain are lost thereby causing the lobes to shrink. FTD can affect behavior, personality, language, and movement;
- Nonfluent variant primary progressive aphasia occurs as a result of a buildup of one of two proteins, either tau or TPD-43 , usually in the front left part of the brain. That part of the brain controls speech and language. As more of the protein builds up in those brain cells, the cells lose their ability to function and eventually die. As more cells die, the affected portion of the brain shrinks; and
- Tay-Sachs is a very rare genetic neurodegenerative disease in which fatty compounds, called gangliosides, do not break down fully because the body produces too little of the enzyme hexosaminidase A (or hex A). Over time, gangliosides build up in the brain and damage brain nerve cells. This affects a person’s mental functioning.
- methods are disclosed that significantly attenuate the progression of neurodegenerative diseases treatable by administration of deuterated arachidonic acid or an ester thereof.
- Such administration is delivered with a dosing regimen that comprises both a loading regimen and a maintenance regimen.
- the loading regimen ensures that there is a rapid onset to therapeutic levels of the deuterated arachidonic acid in vivo to attenuate disease progression. This results in the retention of more functionality in the patient as compared to dosing regimens that require longer periods of time to achieve therapeutic levels.
- the maintenance dose ensures that the therapeutic levels of the deuterated arachidonic acid are maintained in the patient during therapy.
- the deuterated arachidonic acid or ester thereof has one or more deuterium atoms at the bis-allylic sites.
- the deuterated arachidonic acid or ester is 13,13 -D2 -arachidonic acid or an ester thereof, 10, 10,13, 13-D4-arachidonic acid or an ester thereof, or 7,7, 10,10,13,13 -D2-arachidonic acid or an ester thereof.
- a composition of deuterated arachidonic acid or ester thereof which composition comprises on average at least about 80% of the hydrogen atoms at the bis- allylic sites replaced by deuterium atoms.
- the deuterated arachidonic acid or ester thereof comprises on average at least about 80% of the hydrogen atoms at the bis-allylic sites replaced by deuterium atoms and no more than about 35% on average of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
- the deuterated arachidonic acid or ester thereof is 13,13 -D2- arachidonic acid or an ester thereof. [0008] In one embodiment, the deuterated arachidonic acid or ester thereof is 10,10, 13,13- D4-arachidonic acid or an ester thereof.
- the deuterated arachidonic acid or ester thereof is 7,7,10, 10,13,13-D6-arachidonic acid or an ester thereof
- deuterated arachidonic acid is systemically absorbed and incorporated into cells, such as the cell membrane and the mitochondria.
- the deuterated arachidonic acid stabilizes the cell membrane against oxidative damage caused by reactive oxygen species. This, in turn, stops the cascade of lipid peroxidation, thereby minimizing damage to motor neurons where the deuterated arachidonic acid is incorporated.
- concentrations of deuterated arachidonic acid reach a therapeutic level in the motor neurons, the disease progression of neurodegenerative diseases is significantly attenuated.
- the methods described herein provide for rapid onset of a therapeutic concentration of deuterated arachidonic acid in vivo so as to minimize unnecessary loss of functionality in the treated patients suffering from a neurodegenerative disease.
- a method for reducing disease progression of a neurodegenerative disease in an adult patient treatable with deuterated arachidonic acid while providing for rapid onset of therapy comprising periodically administering deuterated arachidonic acid or an ester thereof to the patient with a dosing regimen that comprises a primer dose and a maintenance dose.
- the primer dose comprises periodic administration of deuterated arachidonic acid or an ester thereof. In an embodiment, the primer dose comprises at least about 10 milligrams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the primer dose comprises from about 50 milligrams to about 2 grams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the primer dose comprises from about 0. 10 grams to about 1 gram. In an embodiment, the primer dose is continued for about 15 to about 50 days or from about 30 days to about 45 days, e.g., to rapidly achieve a therapeutic concentration of deuterated arachidonic acid in vivo, thereby reducing the rate of disease progression.
- the maintenance dose is periodically administered. In an embodiment, no more than about 65% of the loading dose of the deuterated arachidonic acid or an ester thereof per day is administered as a maintenance dose. In an embodiment, the maintenance dose is utilized to ensure that the therapeutic concentration of deuterated arachidonic acid is maintained in vivo such that a reduced rate of disease progression is maintained.
- the reduced rate of disease progression is evaluated when compared to the rate of disease progression measured prior to initiation of said method.
- each of said neurodegenerative diseases is mediated at least in part by lipid peroxidation of polyunsaturated fatty acids in neurons of the patient suffering from said neurodegenerative disease.
- said neurodegenerative disease is amyotrophic lateral sclerosis (ALS), Huntington’s Disease, progressive supemuclear palsy (PSP), Friedreich’s ataxia, APO-e4 Alzheimer’s Disease, corticobasal disorder (CBD), frontotemporal dementia (FTD), nonfluent variant primary progressive aphasia (nfvPPA), other tauopathies, or late onset Tay- Sachs.
- ALS amyotrophic lateral sclerosis
- PGP progressive supemuclear palsy
- FTD frontotemporal dementia
- nfvPPA nonfluent variant primary progressive aphasia
- other tauopathies or late onset Tay- Sachs.
- said periodic administration of the loading dose comprises administration of from about 0.05 grams to about 2 grams of deuterated arachidonic acid or an ester thereof per day.
- the loading dose is administered for at least 5 days per week, and preferably 7 days a week.
- the periodic administration of the maintenance dose of deuterated arachidonic acid or an ester thereof per day comprises no more than 55% of the loading dose.
- the maintenance dose is administered per day, or at least 5 days per week, or at least once per week, or at least once per month.
- the maintenance dose comprises no more than 35% of the loading dose which is administered at least once a month.
- the periodic administration of the maintenance dose is calibrated to be an amount of deuterated arachidonic acid or an ester thereof sufficient to replace the amount of deuterated arachidonic acid eliminated from the body.
- the percentreduction in the rate of disease progression is determined by: measuring a natural rate of disease progression in a patient or an average natural rate of disease progression in a cohort of patients prior to initiation of therapy per the methods described herein; measuring the rate of disease progression in said patient or cohort of patients during a period of compliance with the periodic administration of both the loading dose and the maintenance dose; and after said period of compliance from the start of therapy, optionally annualizing the progression rate during the natural history and the progression rate during therapy, calculating the difference between the natural rate and the rate during the period of compliance, dividing the difference by the rate of disease progression during the natural history of the patient, and multiplying by 100.
- the set period of time is between about 1 month and about 24 months, for example about 3 months, about 6 months or about 12 months, or about 18 months or about 24 months. In an embodiment, the set period of time is at least 3 months.
- the methods described herein further comprise restricting the patient’s consumption of excessive dietary polyunsaturated fatty acids during administration of said primer and said maintenance doses.
- kits of parts comprising a set of capsules, each capsule comprising a partial loading dose of deuterated arachidonic acid or an ester thereof, such that two or more of said capsules comprise a complete loading dose per day.
- kits of parts comprising a set of capsules, each capsule comprising a partial loading dose of deuterated arachidonic acid or an ester thereof, such that no more than four of said capsules comprise a complete loading dose per day.
- kits of parts comprising a set of capsules, each capsule comprising a partial maintenance dose of deuterated arachidonic acid or an ester thereof, such that two or more of said capsules comprise a complete maintenance dose per day.
- kits of parts comprising a set of capsules, each capsule comprising a partial maintenance dose of deuterated arachidonic acid or an ester thereof such that one or two of said capsules comprise a complete maintenance dose per day.
- the percentreduction in the rate of disease progression from that occurring during the natural history of the patient and after start of therapy is at least 25%, at least 30%, preferably at least 40%, more preferably at least 65% and most preferably greater than 70% or 80% after 3 or 6 months.
- methods disclosed herein provide for determining a percent reduction in the rate of disease progression by (i) determining a natural rate of disease progression in a patient or an average natural rate of disease progression in a cohort of patients; (ii) determining the rate of disease progression in the patient or cohort of patients during a period of compliance with administration of deuterated arachidonic acid, an ester thereof, or a prodrug thereof ; (iii) measuring the difference between the natural rate of disease progression and the rate during the period of compliance, (iv) optionally annualizing the progression rate during the natural history and the progression rate during therapy; (v) dividing the difference by the natural rate of disease progression and (vi) multiplying by 100.
- whether a therapeutic concentration of deuterated arachidonic acid has been reached in neurons is measured using a reporter cell.
- the reporter cells are red blood cells.
- a concentration of 13 , 13 -D2- arachidonic acid of at least about 3% based on the total number of arachidonic acid, including deuterated arachidonic acid, contained in the red blood cells has been found to correlate with therapeutic results. See, e.g., U.S. Provisional Patent Application No. 63/177,794, filed April 21 , 2021 , which is incorporated by reference in its entirety.
- the patients are placed on a diet that restricts intake of excessive amounts of linoleic acid. This is because linoleic acid competes with arachidonic acid for incorporation into membranes and bioactive pools. Excess linoleic acid will result in diminished amounts of arachidonic acid in these pools.
- dietary components that contribute to excessive amounts of PUFA consumed are restricted including, for example, fish oil pills, products that contain high levels of PUFAs, such as salmon; patients on conventional feeding tubes may also have excessive PUFA intake.
- the methods described herein include both the dosing regimen described above as well as placing the patients on a restrictive diet that avoids excessive ingestion of PUFA components and especially excessive linoleic acid.
- a method for reducing the rate of disease progression in a patient suffering from a neurodegenerative disease treatable with deuterated arachidonic acid comprises administering deuterated arachidonic acid or an ester thereof to the patient with a dosing regimen that comprises a primer dosing and a maintenance dosing schedule which comprise: a) said first dosing component comprises administering to said patient a primer dose of deuterated arachidonic acid or an ester thereof in an amount and for a period of time sufficient to allow for reduction in the rate of disease progression within no more than about 45 days from start of dosing; b) subsequently following said primer dose, initiating a maintenance dose to said patient, said maintenance dose comprises an amount of deuterated arachidonic acid or an ester thereof in an amount sufficient to maintain the concentration of deuterated arachidonic acid in the motor neurons, wherein the amount of deuterated arachidonic acid or ester thereof administered in said maintenance dose is less than the amount administered in said primer dose
- FIG. 1 is a graph showing the percent of 13, 13 -D2 -Arachidonic Acid in red blood cells (RBC) and cerebral spinal fluid (CSF) at the indicated time points after start of treatment with 11, 11 -D2-Linoleic Acid in an adult patient.
- RBC red blood cells
- CSF cerebral spinal fluid
- FIG. 2 is a graph showing the percent of 13, 13 -D2 -Arachidonic Acid in red blood cells (RBC) and cerebral spinal fluid (CSF) at the indicated time points after start of treatment with 11, 11 -D2-Linoleic Acid in juvenile patients.
- the methods of this disclosure include a dosing regimen that is sufficient to provide a therapeutic level of deuterated arachidonic acid in the motor neurons.
- the methods described herein comprise a daily or periodic primer or loading dose that accelerates delivery of deuterated arachidonic acid to the diseased neurons of the patient. This primer dose is continued for a sufficient period of time to achieve a therapeutic concentration of a deuterated arachidonic acid in vivo. At that point, a daily or periodic maintenance dose is employed to maintain the therapeutic concentration of the deuterated arachidonic acid.
- the term “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
- the term “about” when used before a numerical designation, e.g., temperature, time, amount, concentration, and such other, including a range, indicates approximations which may vary by ( + ) or ( - ) 15% , 10%, 5%, 1%, or any subrange or subvalue there between.
- the term “about” when used with regard to a dose amount means that the dose may vary by +/- 10%.
- compositions and methods are intended to mean that the compositions and methods include the recited elements, but not excluding others.
- compositions and methods when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
- arachidonic acid has the numbering system as described below: where each of positions 7, 10 and 13 are bis-allylic positions within the structure.
- the term “deuterated arachidonic acid or an ester thereof ’ refers to 7-D1 -arachidonic acid or an ester thereof; 10- D 1 -arachidonic acid or an ester thereof; 13 -D 1 -arachidonic acid or an ester thereof; 7, 10-D2- arachidonic acid or an ester thereof; 7,13-D2-arachidonic acid or an ester thereof; 10,13-D2- arachidonic acid or an ester thereof; 7,7-D2-arachidonic acid or an ester thereof; 10,10-D2- arachidonic acid or an ester thereof; 13, 13 -D2-arachidonic acid or an ester thereof; 7,10,13- D3 -arachidonic acid or an ester thereof; 7,7, 10 -D3 -arachidonic acid or an ester thereof;
- Preferred D2 -arachidonic acids include 7,7-D2-arachidonic acid or esters thereof;
- Preferred D4 -arachidonic acids or esters thereof include 7,7,10, 10-D4-arachidonic acid or esters thereof; 7,7, 13,13 -D4-arachidonic acid or esters thereof; and 10,10,13,13-04- arachidonic acid or esters thereof.
- 10, 10,13,13 -D4-arachidonic acid can be biosynthesized from 8,8,1 l,l l -D4-gamma linolenic acid or from 10, 10,13, 13-D6-d-homa- gamma linolenic acid. The bioconversion of both of these PUFAs results in 10,10,13,13-04- arachidonic acid.
- Both the 8,8,11,1 l-D4-gamma linolenic acid or the 10,10, 13,13 -D6-d- homa-gamma linolenic acid (or esters of either) can be prepared by ruthenium catalysis as described below provided that such will result in at least 80% deuteration of their bis-allylic positions as well as nominal amounts of deuteration at one or both of the mono-allylic positions (e.g., less than about 25%).
- Preferred D6 -arachidonic acid includes 7,7, 10,10, 13, 13-D6-arachidonic acid or esters thereof including compositions of deuterated arachidonic acid or ester thereof that comprises, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 35% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms.
- an ester thereof refers to a Ci-C 6 alkyl esters, glycerol esters (including monoglycerides, diglycerides and triglycerides), sucrose esters, phosphate esters, and the like.
- the particular ester group employed is not critical provided that the ester is pharmaceutically acceptable (non -toxic and biocompatible).
- the ester is a Ci-Ce alkyl ester which is preferably an ethyl ester.
- phospholipid refers to any and all phospholipids that are components of the cell membrane. Included within this term are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and sphingomyelin. In the motor neurons, the cell membrane is enriched in phospholipids comprising arachidonic acid.
- pathology of a disease refers to the cause, development, structural/functional changes, and natural history associated with that disease.
- natural history means the progression of the disease in the absence of treatment per the methods described herein.
- the term “reduced rate of disease progression” means that the rate of disease progression is attenuated after initiation of treatment as compared to the patient’s natural history.
- the rate of reduction in disease progression using the methods described herein results in a percentage reduction of at least 25% lower or at least 30% lower at a time point, e.g., 1 month to 24 months, e.g., 3 or 6 months, after initiation of therapy when compared to the natural history of the patient.
- the term “therapeutic concentration” means a concentration of a deuterated arachidonic acid that reduces the rate of disease progression by at least 25% or at least 30%. Since measuring the concentration of a deuterated arachidonic acid in the motor neurons or in the spinal fluid of a patient is either not feasible or optimal, the therapeutic concentration is based on the concentration of deuterated arachidonic acid found in red blood cells as provided in the Examples below. Accordingly, any reference made herein to a therapeutic concentration of deuterated arachidonic acid is made by evaluating its concentration in red blood cells.
- the reduction in the rate of disease progression is confirmed by a reduction in the downward slope (flattening the curve) of a patient’s relative muscle functionality during therapy as compared to the downward slope found in the patient’s natural history .
- the differential between the downward slope measured prior to treatment and the slope measured after at least 90 days from initiation of treatment has a flattening level of at least about 30%. So, a change of 7.5 degrees (e.g., a downward slope of 25 degrees during the natural history that is reduced to a downward slope of 17.5 degrees provides for a 40% decrease in the slope).
- the reduction in downward slope evidence that the patient has a reduced rate of disease progression due to the therapy.
- the term “patient” refers to a human patient or a cohort of human patients suffering from a neurodegenerative disease treatable by administration of deuterated arachidonic acid or an esterthereof.
- the term “adult patient” refers to a subject over 18 years of age and suffering from a neurodegenerative disease treatable by administration of deuterated arachidonic acid or an ester thereof.
- the term “loading or primer amount” refers to an amount of a deuterated arachidonic acid or an ester thereof that is sufficient to provide for a reduced rate of disease progression within at least about 45 days after initiation of administration and preferably within 30 days.
- the amount so employed is loaded to accelerate the period of time to reduce the rate of disease progression within this time period.
- less than a loading amount it is understood that such can still provide for therapeutic results but the time period between start of therapy and when therapeutic results are achieved will be longer and, likely, will not achieve the same level of reduction in disease progression.
- the use of the dosing regimens described herein will minimize the time necessary to achieve the desired reduction in the rate of disease progression thereby retaining as much of the patient’s remaining muscle functionality while limiting further loss of functionality.
- the methods described herein are based on the discovery that the primer doses of deuterated arachidonic acid or an ester thereof employed to date are well tolerated by patients and provide for rapid onset of a sufficient in vivo concentration of deuterated arachidonic acid to provide for a reduced and stabilized rate of disease progression.
- the term “maintenance dose” refers to a dose of deuterated arachidonic acid or an ester thereof that is less than the primer dose and is sufficient to maintain a therapeutic concentration of deuterated arachidonic acid in the cell membrane of red blood cells and, hence, in the cell membrane of motor neurons, so as to retain a reduced rate of disease progression.
- the deuterated arachidonic acid or ester thereof is the same compound as used in the loading dose and the maintenance dose.
- periodic dosing refers to a dosing schedule that substantially comports to the dosing described herein.
- periodic dosing includes a patient who is compliant at least 75 percent of the time over a 30 -day period and preferably at least 80% compliant with the dosing regimen described herein.
- the dosing schedule contains a designed pause in dosing.
- a dosing schedule that provides dosing 6 days a week is one form of periodic dosing.
- Another example is allowing the patient to pause administration for from about 3 or 7 or more days (e.g., due to personal reasons) provided that the patient is otherwise at least 75 percent compliant.
- compliance is ascertained by both the loading dose and the maintenance dose.
- the term “cohort” refers to a group of at least 2 patients whose results are to be averaged.
- the term “pharmaceutically acceptable salts” of compounds disclosed herein are within the scope of the methods described herein and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable).
- pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p -toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid).
- inorganic acids such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid
- organic acids e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, o
- the compound When the compound has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g., Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+ ), ammonia or organic amines (e.g., dicyclohexylamine, trimethylamine, trimethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine) or basic amino acids (e.g., arginine, lysine, and ornithine).
- metals such as alkali and earth alkali metals (e.g., Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+ ), ammonia or organic amines (e.g., dicyclohexylamine, trimethylamine, trimethylamine, pyridine, picoline, ethanolamine, diethanol
- excessive amounts of linoleic acid refer to the total intake of linoleic acid in amounts that would reduce the amount of arachidonic acid, including deuterated arachidonic acid, incorporated into the tissue and bioactive pools of the patient.
- each of the neurodegenerative diseases is independent of the underlying etiology of the disease. That is to say that whatever divergent conditions trigger each of these neurodegenerative diseases (the etiology), once triggered the pathology of these diseases involves lipid peroxidation of arachidonic acid in neurons. It should be noted that while deuterated arachidonic acid inhibits lipid peroxidation, there are a number of neurodegenerative diseases that are not treatable by the administration of deuterated arachidonic acid or an ester thereof. Hence, only neurodegenerative diseases that respond to the administration of deuterated arachidonic acid are suitable for use in the methods described herein.
- ALS amyotrophic lateral sclerosis
- tauopathy including progressive supernuclear palsy - PSP
- Friedrich s ataxia
- Huntington’s Disease Corticobasal disorder (CBD)
- Frontotemporal dementia FTD
- Nonfluent variant primary progressive aphasia nfvPPA
- APO-e4 Alzheimer’ s Disease and late onset Tay-Sachs.
- Neurodegenerative diseases that to date have not been shown to respond to treatment with deuterated arachidonic acid or an ester thereof include GPX4 Deficiency, Neuroserpinosis, and ACOX1-GOF.
- the oxidative stress responsible for such peroxidation is due to an imbalance between routine production and detoxification of reactive oxygen species (“ROS”) that leads to an oxidative attack on the lipid membrane of cells.
- ROS reactive oxygen species
- the lipid membrane as well as the endoplasmic reticulum and mitochondria of motor neurons are highly enriched in arachidonic acid (a 20-carbon chain polyunsaturated fatty acid (“PUFA”) having 4 sites of cisunsaturation). Separating each of these 4 sites are 3 bis-allylic methylene groups. These groups are particularly susceptible to oxidative damage due to ROS, and to enzymes such as cyclooxygenases, cytochromes and lipoxygenases, as compared to allylic methylene and methylene groups.
- PUFA 20-carbon chain polyunsaturated fatty acid
- Oxidized arachidonic acid is no longer arachidonic acid. Apart from being dysfunctional and leading to further membrane damage, oxidation of arachidonic acid reduces the local concentration of arachidonic acid and must be replaced. Thus, it is a double hit: a positive bioactive membrane component is converted to a toxic membrane component.
- Oxidized arachidonic acids negatively affect the fluidity and permeability of cell membranes in motor neurons. In addition, they can lead to oxidation of membrane proteins as well as being converted into a large number of highly reactive carbonyl compounds.
- the latter include reactive species such as acrolein, malonic dialdehyde, glyoxal, methylglyoxal, etc. (Negre-Salvayre A, et al. Brit. J. Pharmacol. 2008; 153:6-20).
- alpha, beta -unsaturated aldehydes such as 4- hydroxynon-2-enal (4-HNE; formed from n-6 PUFAs like LA or AA), and corresponding ketoaldehydes (EsterfbauerH, et al. Free Rad. Biol. Med. 1991; 11 :81-128).
- 4-HNE 4- hydroxynon-2-enal
- ketoaldehydes EsterfbauerH, et al. Free Rad. Biol. Med. 1991; 11 :81-128.
- these reactive carbonyls cross-link (bio)molecules through Michael addition or Schiff base formation pathways leading which continues the underlying pathology of the disease.
- ALSFRS-R a standard test referred to as ALSFRS-R which determines the rate of loss of muscle functionality over time and this is used to measure the rate of disease progression.
- This test has 12 components each of which are measured on a 0 (worse) to 4 (best) scale. The ability of a drug to attenuate the rate of disease progression evidences its efficacy . Even a modestreduction in the rate of functionality loss is considered significant.
- the amount of deuterated arachidonic acid administered to the patient must account for the amount of arachidonic acid consumed per day (typically about 100 to 300 mg), the amount of arachidonic acid biogenerated by conversion of linoleic acid, as well as the amount of arachidonic acid already in the body. This means that the concentration of deuterated arachidonic acid in the body as a percent of total arachidonic acid slowly increases until it reaches a therapeutic level.
- any dosing regimen employed must address the patient’s need for rapid onset of therapy to preserve as much functionality for the patient.
- any therapy for treating such neurodegenerative diseases must be effective as soon as practical and preferably within 45 days from start of therapy, and more preferably within a month or less, thereby retaining as much of the patient’s functionality as possible and furthermore providing for substantial reductions in the rate of disease progression.
- Deuterated arachidonic acids are known in the art and also can be made by conventional chemical synthesis.
- a variety of deuterated arachidonic acids, including D2, D4 and D6-arachidonic acids, are described, for example, in Chistyakov, et al., Molecules, 23(12):3331 (2016) as well as in US PatentNos. 10,052,299 and 10,577,304, all of which are incorporated herein by reference in their entireties.
- Esters of these deuterated fatty acids are prepared by conventional techniques well known in the art.
- the methods described herein comprise the administration of deuterated arachidonic acid or an ester thereof to a patient to treat neurodegenerative diseases mediated by reactive oxygen species.
- the deuterated arachidonic acid or esters thereof comprise D2- arachidonic acid or esters thereof, D4-arachidonic acid or esters thereof, D6-arachidonic acid or esters thereof, or mixtures thereof, each as defined herein.
- the deuterated arachidonic acid or esters thereof comprise D2 -arachidonic acid or esters thereof.
- the deuterated arachidonic acid or esters thereof comprise D4 -arachidonic acid or esters thereof.
- the deuterated arachidonic acid or esters thereof comprise D6-arachidonic acid or esters thereof.
- the deuterated arachidonic acid or esters thereof comprise a mixture of D2-arachidonic acid or esters thereof, D4 -arachidonic acid or esters thereof, and/or D6 -arachidonic acid or esters thereof.
- a composition of deuterated arachidonic acid or ester thereof is employed and comprises on average at least about 80% of the hydrogen atoms at the bis - allylic sites replaced by deuterium atoms.
- the deuterated arachidonic acid or ester thereof comprises on average at least about 80% of the hydrogen atoms at the bis-allylic sites replaced by deuterium atoms and no more than about 35% on average of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
- such administration comprises the use of a dosing regimen that includes two dosing components.
- the first dosing component comprises a primer or loading dose of the deuterated arachidonic acid or an ester thereof.
- the second dosing component comprises a maintenance dose of deuterated arachidonic acid or an ester thereof, wherein the amount of the deuterated arachidonic acid or an ester thereof in said second dosing component is less than that in the first dosing component.
- the loading dose comprises at least about 0.05 grams of deuterated arachidonic acid or an ester thereof per day.
- the loading dose for the deuterated arachidonic acid or ester thereof ranges from about 0.05 grams to about 2 grams per day, administered on a periodic basis as described herein.
- the D4-arachidonic acid or esters thereof will require less of a loading dose than the D2-arachidonic acid or esters thereof and the D6-arachidonic acid or ester thereof require less of a loading dose than the D6-arachidonic acid or esters thereof.
- the ability to reduce the amount of deuterated arachidonic acid or esters thereof with higher levels of deuteration is due to the greater extent of protection against lipid peroxidation in vivo. accorded by the increased levels of deuteration. Still further, the dosing of about 0.0.5 grams to about 2 grams per day is measured by the total amount of deuterated arachidonic acid discounting for impurities and the ester portion of the arachidonic acid ester if an ester prodrug is employed. When so employed, the ester group is readily deacylated in the gastrointestinal track.
- the loading dose is from about 0.05 grams to about 1.5 grams per day. In embodiments, the loading dose is from about 0. lO grams to about 1.5 grams per day.
- the loading dose is from about 0. 10 grams to about 1 .25 grams per day. In embodiments, the loading dose is from about 0. 10 grams to about 1 gram per day. In embodiments, the loading dose is from about 0.10 grams to about 0.5 grams per day .
- the loading dose may be any value or subrange within the recited ranges, including endpoints.
- the amount of deuterated arachidonic acid or an ester thereof employed is designed to provide rapid onset of therapy. Such therapy is measured by a reduction in the disease progression of neurodegenerative diseases as described below.
- the primer dose takes into account the various complicating factors, such as the amount of PUFAs consumed by the patient in a given day as well as the general turnover rate of lipids (half-life) in the patient’s neurons.
- the lipid components of neurons are not static but, rather, are exchanged overtime and have a finite half-life in the body. In general, only a fraction of the lipids components in the lipids are replaced each day. In the case of neurons, these cells are rich in arachidonic acid. The turnover of arachidonic acid in these membranes occurs from a stable pool of lipids comprising arachidonic acid in the spinal fluid. In turn, this stable pool is replaced and replenished overtime by arachidonic acid included in the newly consumed lipids by the patient as part of the patient’s diet as well as by biosynthesis of arachidonic acid from linoleic acid. In embodiments, the maintenance dose of deuterated arachidonic acid or ester thereof is titrated such that the amount of deuterated arachidonic acid administered matches the rate of secretion from the body.
- the loading dose of the dosing regimen described herein includes sufficient amounts of deuterated arachidonic acid that are absorbed into the patient. Once maximized, the resulting deuterated arachidonic acid accumulates in the body and reaches a therapeutic concentration in the patient within about 10 to 45 days after the start of therapy. During this process, deuterated arachidonic acid is systemically absorbed into the cells of the body including neurons.
- the loading dose is administered for about 10 to about 50 days. In embodiments, the loading dose is administered for about 15 to about 50 days. In embodiments, the loading dose is administered for about 20 to about 50 days. In embodiments, the loading dose is administered for about 10 to about 45 days. In embodiments, the loading dose is administered for about 15 to about 45 days. In embodiments, the loading dose is administered for about 20 to about 30 days.
- the length of time may be any value or subrange within the recited ranges, including endpoints.
- the loading dose is administered at least 5 days per week. In embodiments, the loading dose is administered at least 7 days per week. In embodiments, the loading dose is administered at least once per week. In embodiments, the loading dose is administered at least once per month.
- the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 65% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 60% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 55% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 50% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 45% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 40% of the loading dose.
- the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 35% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 30% of the loading dose.
- the maintenance dose is administered at least 5 days per week. In embodiments, the maintenance dose is administered at least 7 days per week. In embodiments, the maintenance dose is administered at least once per week. In embodiments, the maintenance dose is administered at least once per month.
- a concentration of at least about 3% and preferably at least about 5%, and more preferably, at least about 8% of 13,13-D2-arachidonic acid when tested at one (1) month after the start of therapy was found to represent a threshold amount required for therapeutic results in the neurons.
- a concentration of at least about 3% and preferably at least about 5%, and more preferably, at least about 8% of 13,13-D2-arachidonic acid when tested at one (1) month after the start of therapy was found to represent a threshold amount required for therapeutic results in the neurons.
- the methods described herein are also based, in part, on the discovery that the dosing regimen set forth herein provides for rapid uptake or accumulation of deuterated arachidonic acid in the lipid membrane of neurons which then stabilizes these membranes against LPO. As a result, there is a substantial reduction in the progression of the neurodegenerative disease. This is believed to be due to the replacement of hydrogen atoms with deuterium atoms in the deuterated arachidonic acid, rendering the deuterated arachidonic acid significantly more stable to ROS than the hydrogen atoms. As above, this stability manifests itself in reducing the cascade of lipid auto -oxidation and, hence, limiting the rate of disease progression.
- the reduction in the progression of this disease can be readily calculated by using the known and established rate functional decline measured by the R — ALS Functional Rating Scale-revised after commencement of drug therapy as compared to the rate of decline prior to drug therapy (natural history of decline).
- the functional decline is typically measured monthly and is evaluated over a period of time, such as every 1 to 24 months, such as every 3 months, every 6 months, or annually. The period of time may be any value or subrange within the recited ranges, including endpoints.
- the rate of functional decline is predicated on measuring an individual’s, or a cohort’s, average for the natural history of disease progression.
- the individual or cohort average for the functional decline is determined at a period of time such as at 3, 6 or 12 months after initiation of therapy.
- the rate of decline based on the average of the natural history of the cohort is set as the denominator.
- the numerator is set as the delta between the rate of the natural history of disease progression and the rate of functional decline after a set period of treatment per this invention .
- the resulting fraction is the multiplied by 100 to give a percent change. The following exemplifies this analysis.
- Cohort A has an average natural history rate of decline in functionality of 28 annualized for a one (1 ) year period. Six (6) months after initiation of treatment per this invention, Cohort A an annualized average rate of decline in functionality has dropped to 14. This provides a delta of 14 degrees. So, using 14 as the numerator and 28 as the denominator and then multiplying result by 100, one obtains a reduction in the annualized rate of decline of 50 percent.
- the methods of this invention provide for an average percent change in reduction in functionality for a cohort of at least 30% and, more preferably, at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%.
- the change in reduction of functionality is measured over a time period, for example 1 month to 24 months, e.g., at 3 months, at 6 months, or annually.
- the rate of decline can be measured over any time period intermediate between 3 months and 1 year.
- the dosing regimen also addresses the challenge of providing for a dosing regimen that allows for rapid onset to therapeutic concentrations of deuterated arachidonic acid to quickly reduce the rate of disease progression in the patient so as to minimize the additional loss of functionality. It is to be understood that reducing the rate of disease progression correlates to longer periods of retained functionality in the patient and likely a longer lifespan. Accordingly, the faster one reaches such a reduced rate, the better off it is for the patient.
- the methods described herein address this challenge by employing a dosing regimen which delivers deuterated arachidonic acid in amounts sufficient to provide for a therapeutic amount to the neurons.
- the deuterated arachidonic acid reduces the degree of LPO which, in turn, effectively limits progression of ALS provided it is administered in appropriate amounts.
- deuterated linoleic acid or an ester thereof can be used to supplement or replace deuterated arachidonic acid or an ester thereof in the loading dose or the maintenance dose provided that replacement is limited to either the loading dose or the replacement dose but not both. This is due to the fact that a portion of 11, 11 -D2-linoleic acid is bioconverted (e.g., convertedwithin the body) to 13, 13-D2-arachidonic acid.
- the total amount so converted is a fraction of the amount of 11,1 l-D2-linoleic acid or ester thereof administered.
- This fractional conversion allows the clinician to titrate the amount of 13,13- D2-arachidonic acid downward by administering 11,11 -D2-linoleic acid or ester thereof.
- This is particularly the case for the maintenance dose where minimal amounts of 13, 13 -D2- arachidonic acid may be required as the literature recognizes that the amount of biogenerated arachidonic acid is low. See, e.g., Tallima, et al., J. Adv. Res., 11 :33 -41 (2016).
- the term “ester thereof’ refers to the same term used with regard to deuterated arachidonic acid or esters thereof.
- a combination therapy can employ a drug that operates via an orthogonal mechanism of action relativeto inhibition of lipid auto -oxidation.
- Suitable drugs for use in combination include, but not limited to, antioxidants such as edaravone, idebenone, mitoquinone, mitoquinol, vitamin C, or vitamin E provided that none of these anti-oxidants that are directed to inhibiting lipid auto-oxidation, riluzole which preferentially blocks TTX- sensitive sodium channels, conventional pain relief mediations, and the like.
- the specific dosing of deuterated arachidonic acid or an ester thereof is accomplished by any number of the accepted modes of administration.
- the actual amount of the drug used in a daily or periodic dose per the methods of this invention, i.e., the active ingredient, is described in detail above.
- the drug can be administered at least once a day, preferably once or twice or three times a day.
- compositions of this invention are not limited to any particular composition or pharmaceutical carrier, as such may vary.
- compounds of this invention will be administered as pharmaceutical compositions by any of a number of known routes of administration.
- a daily or periodic unit dose is preferably divided into subunits having a number of tablets, pills, capsules, and the like.
- each subunit of the daily or periodic unit dose contains about 1 gram of the drug.
- a daily or periodic unit dose of 9 grams of the drug is preferably provided as 9 sub -unit doses containing about 1 gram of the drug.
- the unit dose is taken in one, two or three settings but, if patient compliance is enhanced by taking the daily or periodic unit dose over 2 or 3 settings per day, such is also acceptable.
- compositions as disclosed herein may be manufactured by any of the methods well-known in the art, such as, by conventional mixing, tableting, encapsulating, and the like.
- the compositions as disclosed herein can include one or more physiologically acceptable inactive ingredients that facilitate processing of active molecules into preparations for pharmaceutical use.
- compositions can comprise the drug in combination with at least one pharmaceutically acceptable excipient.
- Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the claimed compounds.
- excipient may be any solid, liquid, or semi-solid that is generally available to one of skill in the art.
- Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
- Other suitable pharmaceutical excipients and their formulations are described in Remington ’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
- compositions as disclosed herein may, if desired, be presentedin a pack or dispenser device each containing a daily or periodic unit dosage containing the drug in the required number of subunits.
- a pack or device may, for example, comprise metal or plastic foil, such as a blister pack, a vial, or any other type of containment.
- the pack or dispenser device maybe accompanied by instructions for administration including, for example, instructions to take all of the subunits constituting the daily or periodic dose contained therein.
- the amount of the drug in a formulation can vary depending on the number of subunits required for the daily or periodic dose of the drug.
- the formulation will contain, on a weight percent (wt %) basis, from about 10 to 99 weight percent of the drug based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
- the compound is present at a level of about 50 to 99 weight percent.
- the drug is encapsulated inside a capsule without the need for any pharmaceutical excipients such as stabilizers, antioxidants, colorants, etc. This minimizes the number of capsules required per day by maximizing the volume of drug in each capsule.
- This example determines the relative concentration of D2-AA in the CSF and in RBCs in order to determine a correlation between these two concentrations.
- a patient was continuously provided with a daily dose of 9 grams of D2-LA ethyl ester (which is 8.64 grams of active discounting for impurities and removal of the ethyl ester) over about a six-month period.
- Periodic samples of blood and SF were taken and the concentration of both D2-LA and D-2AA in both the RBCs and the SF were measured.
- the D2- AA was obtained by deacylation of the ethyl ester of linoleic acid in the gastrointestinal tract followed by conversion of D2-LA in vivo to D2-AA.
- Table 2 shows that the concentration of D2 -LA and D2-AAin the RBCs at 3 months and 6 months for the same patient.
- the concentration of D2-AAin RBC’s at 3 months is less than that at 6 months evidencing the incremental increase in D2-AA over time.
- the ratio of D2-LA to D2-AA in RBCs at 3 and 6 months is represented as 2.5 :1 +/- 0.4 which corresponds favorably to that found in Table 1 .
- This example also determines the concentration of D2-AA in RBCs. Specifically, a cohort of 14 children was provided with a daily dose of 3.9 grams of D2-LA ethyl ester for 1 month followed by 2.9 grams ofD2-LA ethyl ester for the remaining six -month period. Blood samples were taken at 3 months for all but 1 child and at 6 months for all children. The concentration of D2-AA in RBCs was measured. In all cases, the D2-AA was obtained by deacylation of the ethyl ester of linoleic acid in the gastrointestinal tract followed by bioconversion of D2-LA in vivo to D2-AA.
- the amount of D2-AA in the patients’ RBCs averaged at about 3% based on the total amount of AA and D2-AA present evidencing that such a concentration provided for therapeutic results.
- D2-LA acts as a pro-drug of D2-AA
- the 3% amount of D2-AA in red blood cells shown to be therapeutic would be independent of whether it is delivered by in vivo conversion ofD2-LA or by direct administration of D2-AA.
- This example illustrates the reduction in the rate of disease progression in patients with ALS treated by the dosing methods described herein. Specifically, a cohort of 3 patients was placed on a dosing regimen consisting of a first dosing component (primer dose) of about 9 grams of D2-LA ethyl ester daily for a period of at least 30 days and then all three patients were transitioned to a second dosing component (maintenance dose) of 5 grams of D2-LA ethyl ester.
- primary dose of about 9 grams of D2-LA ethyl ester daily for a period of at least 30 days
- second dosing component maintenance dose
- This example was designed to measure the relative protective activity of 13,13 -D2- arachidonic acid as compared to 7,7,10, 10,13,13 -D6-arachidonic acid in protecting murine fibroblasts from lipid peroxidation mediated cell death.
- two different pools of cells were each seeded in 48-well plates and treated with 50 micromolar of erastin. Cells were incubated with either 13,13-D2-arachidonic acid or 7,7, 10,10,13, 13 -D6-arachidonic acid.
- the amount of LA bioconverted to AA is deemed to be in the range of from about 5% to about 30% of the LA consumed.
- the exact conversion rate depends on factors such as the amount of PUFAs consumed, the amount of AA present in the body coupled with feedback loops, any rate limiting enzymatic steps, and the underlying metabolism of the patient. Therefore, if 2 grams of D2-LA successfully achieves about a 3.0 percent (a therapeutic level) of D-2AA in red blood cells as per Comparative Example A above, and if 15% of the D2-LA (approximately half of 5 to 30 percent) is converted to D2-AA, then one can deduce that:
- Example 4 illustrates thatD6-AA is about2 times more active than D2- AA. So, when using D6-AA, one can deduce that it will require slightly less than half as much as D2-AA. So, at a low end, the 0.3 grams of D2-AA would translate into about 0. 15 grams of D6-AA, or perhaps less. As to the loading dose of D4-AA, it will be intermediate between that for D2-AA and D6-AA.
- Example 3 Still further, to achieve the benefits of Example 3 of a significantly reduced rate of loss of functionality, a dose of 9 grams per day ofD2-LA would be required. At a 15% conversion rate, such would translate to 1 .45 grams per day of D2-AA. For D6-AA, a reduction by 50% would provide for about 0.75 grams per day.
- the loading dose of deuterated arachidonic acid or ester thereof is expected to range from about 0.01 grams to about 2 grams per day.
- dosing is from about 0.05 grams to about 1.5 grams per day.
- the loading dose is from about 0.10 grams to about 1.5 grams per day.
- the loading dose is from about 0.10 grams to about 1 .25 grams per day.
- the loading dose is from about 0.10 grams to about 1 gram per day.
- the loading dose is from about 0.10 grams to about 0.5 grams per day, with preferred dosing ranges of from about 0.1 to about 1.5 grams of deuterated arachidonic acid. Other preferred ranges are provided above.
- the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than about 65% of the loading dose. In one embodiment, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 55% of the loading dose. In one embodiment, the maintenance dose of deuterated arachidonic acid or an ester thereof is calibrated to be an amount of deuterated arachidonic acid or an ester thereof sufficient to replace the amount of deuterated arachidonic acid eliminated from the body.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated arachidonic acid or an ester thereof.
Description
METHODS FOR INHIBITING THE PROGRESSION OF NEURODEGENERATIVE DISEASES
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of and is a Continuation of USSN 17/408,285 filed on August 20, 2021, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
[0002] Disclosed are methods for inhibiting the progression of neurodegenerative diseases in humans. The methods use a specific dosing regimen to treat patients suffering from a neurodegenerative disease treatable with a deuterated arachidonic acid or a prodrug thereof. In particular, the dosing regimen provides for rapid onset to a therapeutic concentration in vivo of deuterated arachidonic acid at a level where the progression of the disease is markedly reduced.
BACKGROUND
[0003] There are a number of debilitating neurodegenerative diseases in humans which, despite the best efforts of researchers, remain incurable and often fatal. As such, the best the attending clinician can do is to slow the progression of the disease and, where possible, maintain a meaningful quality of life for the patient for as long as possible. Examples of such neurodegenerative diseases include the following:
• amyotrophic lateral sclerosis (ALS) which is a late-onset, progressive neurological disease with its corresponding pathological hallmarks including progressive muscle weakness, muscle atrophy and spasticity all of which reflect the degeneration and death of upper and/or lower motor neurons. Once diagnosed, most patients undergo a rapid rate of disease progression terminating in death typically within 3 to 4 years with some patients succumbing even earlier;
• tauopathy is a subgroup of Lewy body diseases or proteinopathies and comprises neurodegenerative conditions involving the aggregation of tau protein into insoluble tangles. These aggregates / tangles form from hyperphosphorylation of tau protein in the human brain. Specific conditions related to tauopathy include, but are not limited to, argyrophilic grain disease (AGD), chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), ganglioglioma, gangliocytoma, lipofuscinosis, lytico-
bodig disease, meningioangiomatosis, pantothenate kinase-associated neurodegeneration (PKAN), Pick’s disease, postencephalitic parkinsonism, primary age-related tau op athy (PART), Steele-Richardson-Olszewski syndrome (SROS), and subacute sclerosing panencephalitis (SSPE). Wang et al., Nature Rev. Neurosci.
2016; 17:5 and Arendt etal., Brain Res. Bulletin 2016; 126:238. Tauopathies often overlap with synucleinopathies.
• Steele-Richardson-Olszewski syndrome or progressive supranuclear palsy (PSP) is one example of a neurodegenerative disease mediated at least in part by tauopathy and involves the gradual deterioration and death of specific volumes of the brain. The condition leads to symptoms including loss of balance, slowing of movement, difficulty moving the eyes, and dementia. A variant in the gene for tau protein called the Hl haplotype, located on chromosome 17, hasbeen linked to PSP. Besides tauopathy, mitochondrial dysfunction seems to be a factor involved in PSP. Especially, mitochondrial complex I inhibitors are implicated in PSP-like brain injuries;
® Friedreich’ s ataxia is an autosomal-recessive genetic disease that causes difficulty walking, a loss of sensation in the arms and legs, and impaired speech that worsens over time. The pathology of this neurodegenerative disease involves degeneration of nerve tissue in the spinal cord;
® Huntington’s disease is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain;
• Corticobasal disorder (CBD) is a rare neurodegenerative disease characterized by
• gradual worsening problems with movement, speech, memory and swallowing. It’s often also called corticobasal syndrome (CBS). CBD is caused by increasing numbers of brain cells becoming damaged or dying over time;
• Frontotemporal dementia (FTD) is a neurodegenerative disease and a common cause of dementia. It is characterized by a group of disorders that occur when nerve cells in the frontal temporal lobes of the brain are lost thereby causing the lobes to shrink. FTD can affect behavior, personality, language, and movement;
• Nonfluent variant primary progressive aphasia (nfvPPA) occurs as a result of a buildup of one of two proteins, either tau or TPD-43 , usually in the front left part of the brain. That part of the brain controls speech and language. As more of the protein
builds up in those brain cells, the cells lose their ability to function and eventually die. As more cells die, the affected portion of the brain shrinks; and
• late onset Tay-Sachs is a very rare genetic neurodegenerative disease in which fatty compounds, called gangliosides, do not break down fully because the body produces too little of the enzyme hexosaminidase A (or hex A). Over time, gangliosides build up in the brain and damage brain nerve cells. This affects a person’s mental functioning.
[0004] There remains a need for treatments for these and other neurodegenerative diseases.
SUMMARY
[0005] In one embodiment, methods are disclosed that significantly attenuate the progression of neurodegenerative diseases treatable by administration of deuterated arachidonic acid or an ester thereof. Such administration is delivered with a dosing regimen that comprises both a loading regimen and a maintenance regimen. The loading regimen ensures that there is a rapid onset to therapeutic levels of the deuterated arachidonic acid in vivo to attenuate disease progression. This results in the retention of more functionality in the patient as compared to dosing regimens that require longer periods of time to achieve therapeutic levels. The maintenance dose ensures that the therapeutic levels of the deuterated arachidonic acid are maintained in the patient during therapy.
[0006] In one embodiment, the deuterated arachidonic acid or ester thereof has one or more deuterium atoms at the bis-allylic sites. In one embodiment, the deuterated arachidonic acid or ester is 13,13 -D2 -arachidonic acid or an ester thereof, 10, 10,13, 13-D4-arachidonic acid or an ester thereof, or 7,7, 10,10,13,13 -D2-arachidonic acid or an ester thereof. In another embodiment, there is provided a composition of deuterated arachidonic acid or ester thereof which composition comprises on average at least about 80% of the hydrogen atoms at the bis- allylic sites replaced by deuterium atoms. In one embodiment, the deuterated arachidonic acid or ester thereof comprises on average at least about 80% of the hydrogen atoms at the bis-allylic sites replaced by deuterium atoms and no more than about 35% on average of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
[0007] In one embodiment, the deuterated arachidonic acid or ester thereof is 13,13 -D2- arachidonic acid or an ester thereof.
[0008] In one embodiment, the deuterated arachidonic acid or ester thereof is 10,10, 13,13- D4-arachidonic acid or an ester thereof.
[0009] In one embodiment, the deuterated arachidonic acid or ester thereof is 7,7,10, 10,13,13-D6-arachidonic acid or an ester thereof
[0010] Without being limited by theory, once administered, deuterated arachidonic acid is systemically absorbed and incorporated into cells, such as the cell membrane and the mitochondria. In neurons, the deuterated arachidonic acid stabilizes the cell membrane against oxidative damage caused by reactive oxygen species. This, in turn, stops the cascade of lipid peroxidation, thereby minimizing damage to motor neurons where the deuterated arachidonic acid is incorporated. When concentrations of deuterated arachidonic acid reach a therapeutic level in the motor neurons, the disease progression of neurodegenerative diseases is significantly attenuated.
[0011] The methods described herein provide for rapid onset of a therapeutic concentration of deuterated arachidonic acid in vivo so as to minimize unnecessary loss of functionality in the treated patients suffering from a neurodegenerative disease. In one embodiment, there is provided a method for reducing disease progression of a neurodegenerative disease in an adult patient treatable with deuterated arachidonic acid while providing for rapid onset of therapy, the method comprising periodically administering deuterated arachidonic acid or an ester thereof to the patient with a dosing regimen that comprises a primer dose and a maintenance dose.
[0012] In an embodiment, the primer dose comprises periodic administration of deuterated arachidonic acid or an ester thereof. In an embodiment, the primer dose comprises at least about 10 milligrams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the primer dose comprises from about 50 milligrams to about 2 grams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the primer dose comprises from about 0. 10 grams to about 1 gram. In an embodiment, the primer dose is continued for about 15 to about 50 days or from about 30 days to about 45 days, e.g., to rapidly achieve a therapeutic concentration of deuterated arachidonic acid in vivo, thereby reducing the rate of disease progression.
[0013] In an embodiment, after completion of the primer dose, the maintenance dose is periodically administered. In an embodiment, no more than about 65% of the loading dose of
the deuterated arachidonic acid or an ester thereof per day is administered as a maintenance dose. In an embodiment, the maintenance dose is utilized to ensure that the therapeutic concentration of deuterated arachidonic acid is maintained in vivo such that a reduced rate of disease progression is maintained.
[0014] In an embodiment, the reduced rate of disease progression is evaluated when compared to the rate of disease progression measured prior to initiation of said method. In an embodiment, each of said neurodegenerative diseases is mediated at least in part by lipid peroxidation of polyunsaturated fatty acids in neurons of the patient suffering from said neurodegenerative disease.
[0015] In one embodiment, said neurodegenerative disease is amyotrophic lateral sclerosis (ALS), Huntington’s Disease, progressive supemuclear palsy (PSP), Friedreich’s ataxia, APO-e4 Alzheimer’s Disease, corticobasal disorder (CBD), frontotemporal dementia (FTD), nonfluent variant primary progressive aphasia (nfvPPA), other tauopathies, or late onset Tay- Sachs.
[0016] In one embodiment, said periodic administration of the loading dose comprises administration of from about 0.05 grams to about 2 grams of deuterated arachidonic acid or an ester thereof per day. In embodiments, the loading dose is administered for at least 5 days per week, and preferably 7 days a week.
[0017] In one embodiment, the periodic administration of the maintenance dose of deuterated arachidonic acid or an ester thereof per day comprises no more than 55% of the loading dose. In embodiments, the maintenance dose is administered per day, or at least 5 days per week, or at least once per week, or at least once per month. In another embodiment, the maintenance dose comprises no more than 35% of the loading dose which is administered at least once a month.
[0018] In one embodiment, the periodic administration of the maintenance dose is calibrated to be an amount of deuterated arachidonic acid or an ester thereof sufficient to replace the amount of deuterated arachidonic acid eliminated from the body.
[0019] In one embodiment, the percentreduction in the rate of disease progression is determined by:
measuring a natural rate of disease progression in a patient or an average natural rate of disease progression in a cohort of patients prior to initiation of therapy per the methods described herein; measuring the rate of disease progression in said patient or cohort of patients during a period of compliance with the periodic administration of both the loading dose and the maintenance dose; and after said period of compliance from the start of therapy, optionally annualizing the progression rate during the natural history and the progression rate during therapy, calculating the difference between the natural rate and the rate during the period of compliance, dividing the difference by the rate of disease progression during the natural history of the patient, and multiplying by 100.
[0020] In one embodiment, the set period of time is between about 1 month and about 24 months, for example about 3 months, about 6 months or about 12 months, or about 18 months or about 24 months. In an embodiment, the set period of time is at least 3 months.
[0021] In one embodiment, the methods described herein further comprise restricting the patient’s consumption of excessive dietary polyunsaturated fatty acids during administration of said primer and said maintenance doses.
[0022] In one embodiment, there is provided a kit of parts comprising a set of capsules, each capsule comprising a partial loading dose of deuterated arachidonic acid or an ester thereof, such that two or more of said capsules comprise a complete loading dose per day.
[0023] In one embodiment, there is provided a kit of parts comprising a set of capsules, each capsule comprising a partial loading dose of deuterated arachidonic acid or an ester thereof, such that no more than four of said capsules comprise a complete loading dose per day.
[0024] In one embodiment, there is provided a kit of parts comprising a set of capsules, each capsule comprising a partial maintenance dose of deuterated arachidonic acid or an ester thereof, such that two or more of said capsules comprise a complete maintenance dose per day.
[0025] In one embodiment, there is provided a kit of parts comprising a set of capsules, each capsule comprising a partial maintenance dose of deuterated arachidonic acid or an ester thereof such that one or two of said capsules comprise a complete maintenance dose per day.
[0026] In one embodiment, the percentreduction in the rate of disease progression from that occurring during the natural history of the patient and after start of therapy is at least 25%, at least 30%, preferably at least 40%, more preferably at least 65% and most preferably greater than 70% or 80% after 3 or 6 months. Accordingly, in some embodiments, methods disclosed herein provide for determining a percent reduction in the rate of disease progression by (i) determining a natural rate of disease progression in a patient or an average natural rate of disease progression in a cohort of patients; (ii) determining the rate of disease progression in the patient or cohort of patients during a period of compliance with administration of deuterated arachidonic acid, an ester thereof, or a prodrug thereof ; (iii) measuring the difference between the natural rate of disease progression and the rate during the period of compliance, (iv) optionally annualizing the progression rate during the natural history and the progression rate during therapy; (v) dividing the difference by the natural rate of disease progression and (vi) multiplying by 100.
[0027] In one embodiment, whether a therapeutic concentration of deuterated arachidonic acid has been reached in neurons is measured using a reporter cell. In an embodiment, the reporter cells are red blood cells. In the case of red blood cells, a concentration of 13 , 13 -D2- arachidonic acid of at least about 3% based on the total number of arachidonic acid, including deuterated arachidonic acid, contained in the red blood cells has been found to correlate with therapeutic results. See, e.g., U.S. Provisional Patent Application No. 63/177,794, filed April 21 , 2021 , which is incorporated by reference in its entirety.
[0028] In one embodiment, the patients are placed on a diet that restricts intake of excessive amounts of linoleic acid. This is because linoleic acid competes with arachidonic acid for incorporation into membranes and bioactive pools. Excess linoleic acid will result in diminished amounts of arachidonic acid in these pools. Generally, dietary components that contribute to excessive amounts of PUFA consumed are restricted including, for example, fish oil pills, products that contain high levels of PUFAs, such as salmon; patients on conventional feeding tubes may also have excessive PUFA intake. In a preferred embodiment, the methods described herein include both the dosing regimen described above as well as placing the patients on a restrictive diet that avoids excessive ingestion of PUFA components and especially excessive linoleic acid.
[0029] In one embodiment, there is provided a method for reducing the rate of disease progression in a patient suffering from a neurodegenerative disease treatable with deuterated
arachidonic acid, which method comprises administering deuterated arachidonic acid or an ester thereof to the patient with a dosing regimen that comprises a primer dosing and a maintenance dosing schedule which comprise: a) said first dosing component comprises administering to said patient a primer dose of deuterated arachidonic acid or an ester thereof in an amount and for a period of time sufficient to allow for reduction in the rate of disease progression within no more than about 45 days from start of dosing; b) subsequently following said primer dose, initiating a maintenance dose to said patient, said maintenance dose comprises an amount of deuterated arachidonic acid or an ester thereof in an amount sufficient to maintain the concentration of deuterated arachidonic acid in the motor neurons, wherein the amount of deuterated arachidonic acid or ester thereof administered in said maintenance dose is less than the amount administered in said primer dose; and optionally: c) monitoring the concentration of deuterated arachidonic acid in the patient to ensure that the patient is maintaining a therapeutic concentration; and d) increasing the dosing of deuterated arachidonic acid or an ester thereof when said concentration is deemed to be less than a therapeutic amount.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] FIG. 1 is a graph showing the percent of 13, 13 -D2 -Arachidonic Acid in red blood cells (RBC) and cerebral spinal fluid (CSF) at the indicated time points after start of treatment with 11, 11 -D2-Linoleic Acid in an adult patient.
[0031] FIG. 2 is a graph showing the percent of 13, 13 -D2 -Arachidonic Acid in red blood cells (RBC) and cerebral spinal fluid (CSF) at the indicated time points after start of treatment with 11, 11 -D2-Linoleic Acid in juvenile patients.
DETAILED DESCRIPTION
[0032] This disclosure is directed to methods for treating neurodegenerative diseases to significantly slow the rate of disease progression in a patient. In one embodiment, the methods of this disclosure include a dosing regimen that is sufficient to provide a therapeutic level of deuterated arachidonic acid in the motor neurons. In another embodiment, the methods described herein comprise a daily or periodic primer or loading dose that accelerates delivery of deuterated arachidonic acid to the diseased neurons of the patient. This primer
dose is continued for a sufficient period of time to achieve a therapeutic concentration of a deuterated arachidonic acid in vivo. At that point, a daily or periodic maintenance dose is employed to maintain the therapeutic concentration of the deuterated arachidonic acid.
[0033] Prior to discussing this invention in more detail, the following terms will first be defined. Terms that are not defined are given their definition in context or are given their medically acceptable definition.
[0034] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
[0035] As used herein, the term “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0036] As used herein, the term “about” when used before a numerical designation, e.g., temperature, time, amount, concentration, and such other, including a range, indicates approximations which may vary by ( + ) or ( - ) 15% , 10%, 5%, 1%, or any subrange or subvalue there between. Preferably, the term “about” when used with regard to a dose amount means that the dose may vary by +/- 10%.
[0037] As used herein, the term “comprising” or “comprises” is intended to mean that the compositions and methods include the recited elements, but not excluding others.
[0038] As used herein, the term “consisting essentially of’ when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
[0039] As used herein, the term “consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
[0040] As used herein, arachidonic acid has the numbering system as described below:
where each of positions 7, 10 and 13 are bis-allylic positions within the structure.
[0041] As used herein and unless the context dictates otherwise, the term “deuterated arachidonic acid or an ester thereof ’ refers to 7-D1 -arachidonic acid or an ester thereof; 10- D 1 -arachidonic acid or an ester thereof; 13 -D 1 -arachidonic acid or an ester thereof; 7, 10-D2- arachidonic acid or an ester thereof; 7,13-D2-arachidonic acid or an ester thereof; 10,13-D2- arachidonic acid or an ester thereof; 7,7-D2-arachidonic acid or an ester thereof; 10,10-D2- arachidonic acid or an ester thereof; 13, 13 -D2-arachidonic acid or an ester thereof; 7,10,13- D3 -arachidonic acid or an ester thereof; 7,7, 10 -D3 -arachidonic acid or an ester thereof;
7.10.10-D3-arachidonic acid or an esterthereof; 7,13,13-D3-arachidonic acid or an ester thereof; 10,10,13-D3-arachidonic acid or an esterthereof; 10,13,13 -D3-arachidonic acid or an esterthereof; 7,7,10,13-D4-arachidonic acid or an esterthereof; 7,7, 10,10-D4-arachidonic acid or an esterthereof; 7,10,10, 13-D4-arachidonic acid or an esterthereof; 7,10,13, 13-04- arachidonic acid or an esterthereof; 7,7,13,13-D4-arachidonic acid or an esterthereof;
10,10,13,13-D4-arachidonic acid or an esterthereof; 7,7,10, 10,13 -D5 -arachidonic acid or an esterthereof; 7,7,10,13,13-D5-arachidonic acid or an esterthereof; 7,10,10, 13,13-05- arachidonic acid or ester thereof; 7,7, 10,10, 13, 13 -D6-arachidonic acid or ester thereof; or mixtures of any two or more.
[0042] Preferred D2 -arachidonic acids include 7,7-D2-arachidonic acid or esters thereof;
10.10-D2-arachidonic acid or esters thereof; and 13,13-D2-arachidonic acid or esters thereof.
[0043] Preferred D4 -arachidonic acids or esters thereof include 7,7,10, 10-D4-arachidonic acid or esters thereof; 7,7, 13,13 -D4-arachidonic acid or esters thereof; and 10,10,13,13-04- arachidonic acid or esters thereof. In one embodiment, 10, 10,13,13 -D4-arachidonic acid can be biosynthesized from 8,8,1 l,l l -D4-gamma linolenic acid or from 10, 10,13, 13-D6-d-homa- gamma linolenic acid. The bioconversion of both of these PUFAs results in 10,10,13,13-04- arachidonic acid. Both the 8,8,11,1 l-D4-gamma linolenic acid or the 10,10, 13,13 -D6-d- homa-gamma linolenic acid (or esters of either) can be prepared by ruthenium catalysis as
described below provided that such will result in at least 80% deuteration of their bis-allylic positions as well as nominal amounts of deuteration at one or both of the mono-allylic positions (e.g., less than about 25%).
[0044] Preferred D6 -arachidonic acid includes 7,7, 10,10, 13, 13-D6-arachidonic acid or esters thereof including compositions of deuterated arachidonic acid or ester thereof that comprises, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 35% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms. For example, in the case of 80% deuteration of the 3 bis-allylic sites and 35% deuteration of the mono-allylic sites, the total amount of deuterium is (6 x 0.8) + (4 x 0.35) = 6.2 exclusive of the naturally occurring amount of deuterium in each of the remaining methylene and methyl groups within the structure.
[0045] As used herein and unless the context dictates otherwise, the term “an ester thereof ’ refers to a Ci-C6 alkyl esters, glycerol esters (including monoglycerides, diglycerides and triglycerides), sucrose esters, phosphate esters, and the like. The particular ester group employed is not critical provided that the ester is pharmaceutically acceptable (non -toxic and biocompatible). In one embodiment, the ester is a Ci-Ce alkyl ester which is preferably an ethyl ester.
[0046] As used herein, the term “phospholipid” refers to any and all phospholipids that are components of the cell membrane. Included within this term are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and sphingomyelin. In the motor neurons, the cell membrane is enriched in phospholipids comprising arachidonic acid.
[0047] As used herein, the term “pathology of a disease” refers to the cause, development, structural/functional changes, and natural history associated with that disease. The term “natural history” means the progression of the disease in the absence of treatment per the methods described herein.
[0048] As used herein, the term “reduced rate of disease progression” means that the rate of disease progression is attenuated after initiation of treatment as compared to the patient’s natural history. In one case, the rate of reduction in disease progression using the methods described herein results in a percentage reduction of at least 25% lower or at least 30% lower
at a time point, e.g., 1 month to 24 months, e.g., 3 or 6 months, after initiation of therapy when compared to the natural history of the patient.
[0049] The term “therapeutic concentration” means a concentration of a deuterated arachidonic acid that reduces the rate of disease progression by at least 25% or at least 30%. Since measuring the concentration of a deuterated arachidonic acid in the motor neurons or in the spinal fluid of a patient is either not feasible or optimal, the therapeutic concentration is based on the concentration of deuterated arachidonic acid found in red blood cells as provided in the Examples below. Accordingly, any reference made herein to a therapeutic concentration of deuterated arachidonic acid is made by evaluating its concentration in red blood cells.
[0050] Alternatively, the reduction in the rate of disease progression is confirmed by a reduction in the downward slope (flattening the curve) of a patient’s relative muscle functionality during therapy as compared to the downward slope found in the patient’s natural history . Typically, the differential between the downward slope measured prior to treatment and the slope measured after at least 90 days from initiation of treatment has a flattening level of at least about 30%. So, a change of 7.5 degrees (e.g., a downward slope of 25 degrees during the natural history that is reduced to a downward slope of 17.5 degrees provides for a 40% decrease in the slope). In any case, the reduction in downward slope evidence that the patient has a reduced rate of disease progression due to the therapy.
[0051] As used herein, the term “patient” refers to a human patient or a cohort of human patients suffering from a neurodegenerative disease treatable by administration of deuterated arachidonic acid or an esterthereof. The term “adult patient” refers to a subject over 18 years of age and suffering from a neurodegenerative disease treatable by administration of deuterated arachidonic acid or an ester thereof.
[0052] As used herein, the term “loading or primer amount” refers to an amount of a deuterated arachidonic acid or an ester thereof that is sufficient to provide for a reduced rate of disease progression within at least about 45 days after initiation of administration and preferably within 30 days. The amount so employed is loaded to accelerate the period of time to reduce the rate of disease progression within this time period. When less than a loading amount is used, it is understood that such can still provide for therapeutic results but the time period between start of therapy and when therapeutic results are achieved will be
longer and, likely, will not achieve the same level of reduction in disease progression. Moreover, given the progressive nature of these neurodegenerative diseases, the use of the dosing regimens described herein will minimize the time necessary to achieve the desired reduction in the rate of disease progression thereby retaining as much of the patient’s remaining muscle functionality while limiting further loss of functionality.
[0053] The methods described herein are based on the discovery that the primer doses of deuterated arachidonic acid or an ester thereof employed to date are well tolerated by patients and provide for rapid onset of a sufficient in vivo concentration of deuterated arachidonic acid to provide for a reduced and stabilized rate of disease progression.
[0054] As used herein, the term “maintenance dose” refers to a dose of deuterated arachidonic acid or an ester thereof that is less than the primer dose and is sufficient to maintain a therapeutic concentration of deuterated arachidonic acid in the cell membrane of red blood cells and, hence, in the cell membrane of motor neurons, so as to retain a reduced rate of disease progression. In one embodiment, the deuterated arachidonic acid or ester thereof is the same compound as used in the loading dose and the maintenance dose.
[0055] As used herein, the term “periodic dosing” refers to a dosing schedule that substantially comports to the dosing described herein. Stated differently, periodic dosing includes a patient who is compliant at least 75 percent of the time over a 30 -day period and preferably at least 80% compliant with the dosing regimen described herein. In embodiments, the dosing schedule contains a designed pause in dosing. For example, a dosing schedule that provides dosing 6 days a week is one form of periodic dosing. Another example is allowing the patient to pause administration for from about 3 or 7 or more days (e.g., due to personal reasons) provided that the patient is otherwise at least 75 percent compliant. Also, for patients who transition from the loading dose to the maintenance dose, compliance is ascertained by both the loading dose and the maintenance dose.
[0056] The term “cohort” refers to a group of at least 2 patients whose results are to be averaged.
[0057] As used herein, the term “pharmaceutically acceptable salts” of compounds disclosed herein are within the scope of the methods described herein and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable). When the
compound has a basic group, such as, for example, an amino group, pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p -toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid). When the compound has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g., Na+, Li+, K+, Ca2+, Mg2+, Zn2+), ammonia or organic amines (e.g., dicyclohexylamine, trimethylamine, trimethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine) or basic amino acids (e.g., arginine, lysine, and ornithine). Such salts can be prepared in situ during isolation and purification of the compounds or by separately reacting the purified compound in its free base or free acid form with a suitable acid or base, respectively, and isolating the salt thus formed.
[0058] The phrase “excessive amounts of linoleic acid”, or “excessive linoleic acid intake,” and the like refer to the total intake of linoleic acid in amounts that would reduce the amount of arachidonic acid, including deuterated arachidonic acid, incorporated into the tissue and bioactive pools of the patient.
Pathology
[0059] The underlying pathology of each of the neurodegenerative diseases is independent of the underlying etiology of the disease. That is to say that whatever divergent conditions trigger each of these neurodegenerative diseases (the etiology), once triggered the pathology of these diseases involves lipid peroxidation of arachidonic acid in neurons. It should be noted that while deuterated arachidonic acid inhibits lipid peroxidation, there are a number of neurodegenerative diseases that are not treatable by the administration of deuterated arachidonic acid or an ester thereof. Hence, only neurodegenerative diseases that respond to the administration of deuterated arachidonic acid are suitable for use in the methods described herein. These include amyotrophic lateral sclerosis (ALS), tauopathy (including progressive supernuclear palsy - PSP), Friedrich’s ataxia, Huntington’s Disease, Corticobasal disorder (CBD), Frontotemporal dementia (FTD), Nonfluent variant primary progressive aphasia (nfvPPA), APO-e4 Alzheimer’ s Disease, and late onset Tay-Sachs.
[0060] Neurodegenerative diseases that to date have not been shown to respond to treatment with deuterated arachidonic acid or an ester thereof include GPX4 Deficiency, Neuroserpinosis, and ACOX1-GOF.
[0061] As to the specifics, the discovery of several aldehydes that easily reacted with sulfhydryl groups, resultingin the inhibition of vital metabolic processes, led to the association of polyunsaturated fatty acid peroxidation as a component of the pathology of many of neurodegenerative diseases (Schauenstein, E.; Esterbauer, H. Formation and properties of reactive aldehydes. Ciba Found. Symp. (67):225-244; 1978). Whether as a primary cause of disease or a secondary consequence, such lipid peroxidation is attributed to oxidative stress, which leads to neural death and this implicatedin the progression of a number of neurodegenerative diseases.
[0062] The oxidative stress responsible for such peroxidation is due to an imbalance between routine production and detoxification of reactive oxygen species (“ROS”) that leads to an oxidative attack on the lipid membrane of cells. The lipid membrane as well as the endoplasmic reticulum and mitochondria of motor neurons are highly enriched in arachidonic acid (a 20-carbon chain polyunsaturated fatty acid (“PUFA”) having 4 sites of cisunsaturation). Separating each of these 4 sites are 3 bis-allylic methylene groups. These groups are particularly susceptible to oxidative damage due to ROS, and to enzymes such as cyclooxygenases, cytochromes and lipoxygenases, as compared to allylic methylene and methylene groups. Oxidized arachidonic acid is no longer arachidonic acid. Apart from being dysfunctional and leading to further membrane damage, oxidation of arachidonic acid reduces the local concentration of arachidonic acid and must be replaced. Thus, it is a double hit: a positive bioactive membrane component is converted to a toxic membrane component.
[0063] Moreover, once a bis-allylic methylene group in one arachidonic acid is oxidized by a ROS, a cascade of further oxidation of other arachidonic acid groups in the lipid membrane occurs. This is because a single ROS generates oxidation of a first arachidonic acid component through a free radical mechanism which, in turn, can oxidize a neighboring arachidonic acid through the same free radical mechanism which yet again can oxidize another neighboring arachidonic acid in a process referred to as lipid chain auto -oxidation. The resulting damage includes a significant number of oxidized arachidonic acid components in the cell membrane.
[0064] Oxidized arachidonic acids negatively affect the fluidity and permeability of cell membranes in motor neurons. In addition, they can lead to oxidation of membrane proteins as well as being converted into a large number of highly reactive carbonyl compounds. The latter include reactive species such as acrolein, malonic dialdehyde, glyoxal, methylglyoxal, etc. (Negre-Salvayre A, et al. Brit. J. Pharmacol. 2008; 153:6-20). The most prominent products of arachidonic acid oxidation are alpha, beta -unsaturated aldehydes such as 4- hydroxynon-2-enal (4-HNE; formed from n-6 PUFAs like LA or AA), and corresponding ketoaldehydes (EsterfbauerH, et al. Free Rad. Biol. Med. 1991; 11 :81-128). As noted above, these reactive carbonyls cross-link (bio)molecules through Michael addition or Schiff base formation pathways leading which continues the underlying pathology of the disease.
Disease Progression
[0065] When a patient is diagnosed with a specific neurodegenerative disease, the clinician evaluates that patient’ s rate of disease progression by assessing the patient’ s loss of functionality in the absence of therapy as described herein. That rate is referred to as the “natural history” of the disease and is typically measured by standardized tests that measure the extent of a patient’s functionality over a set period of time. For example, in the case of ALS, there is a standard test referred to as ALSFRS-R which determines the rate of loss of muscle functionality over time and this is used to measure the rate of disease progression. This test has 12 components each of which are measured on a 0 (worse) to 4 (best) scale. The ability of a drug to attenuate the rate of disease progression evidences its efficacy . Even a modestreduction in the rate of functionality loss is considered significant.
[0066] Once therapy with a deuterated arachidonic acid is initiated, the buildup of this compound in vivo is an incremental process limited by both physiology as well as the turnover rate of arachidonic acid in the patient. Unlike conventional drug therapy where the drug has a very short half-life in vivo, the mechanism of action of deuterated arachidonic acid depends on it achieving and maintaining a certain concentration among all arachidonic acid membranes. It is therefore desirable to have a long half-life and a high threshold to therapy. This is due to the fact that arachidonic acid constitutes both a consumable food product as well as a product that can be biosynthesized from linoleic acid. Taken together, the amount of deuterated arachidonic acid administered to the patient must account for the amount of arachidonic acid consumed per day (typically about 100 to 300 mg), the amount of arachidonic acid biogenerated by conversion of linoleic acid, as well as the amount of
arachidonic acid already in the body. This means thatthe concentration of deuterated arachidonic acid in the body as a percent of total arachidonic acid slowly increases until it reaches a therapeutic level.
[0067] Given the rapid loss of functionality in patients with neurodegenerative diseases, any dosing regimen employed must address the patient’s need for rapid onset of therapy to preserve as much functionality for the patient. Hence, any therapy for treating such neurodegenerative diseases must be effective as soon as practical and preferably within 45 days from start of therapy, and more preferably within a month or less, thereby retaining as much of the patient’s functionality as possible and furthermore providing for substantial reductions in the rate of disease progression.
Compound Preparation
[0068] Deuterated arachidonic acids are known in the art and also can be made by conventional chemical synthesis. In addition, a variety of deuterated arachidonic acids, including D2, D4 and D6-arachidonic acids, are described, for example, in Chistyakov, et al., Molecules, 23(12):3331 (2018) as well as in US PatentNos. 10,052,299 and 10,577,304, all of which are incorporated herein by reference in their entireties. Esters of these deuterated fatty acids are prepared by conventional techniques well known in the art.
Methodology - 13,13 -D 2- Arachidonic Acid or Ester Thereof
[0069] The methods described herein comprise the administration of deuterated arachidonic acid or an ester thereof to a patient to treat neurodegenerative diseases mediated by reactive oxygen species.
Treatment with Deuterated-Arachidonic acids or esters thereof
[0070] In one embodiment, the deuterated arachidonic acid or esters thereof comprise D2- arachidonic acid or esters thereof, D4-arachidonic acid or esters thereof, D6-arachidonic acid or esters thereof, or mixtures thereof, each as defined herein. In an embodiment, the deuterated arachidonic acid or esters thereof comprise D2 -arachidonic acid or esters thereof. In an embodiment, the deuterated arachidonic acid or esters thereof comprise D4 -arachidonic acid or esters thereof. In an embodiment, the deuterated arachidonic acid or esters thereof comprise D6-arachidonic acid or esters thereof. In an embodiment, the deuterated arachidonic acid or esters thereof comprise a mixture of D2-arachidonic acid or esters
thereof, D4 -arachidonic acid or esters thereof, and/or D6 -arachidonic acid or esters thereof. In one embodiment, a composition of deuterated arachidonic acid or ester thereof is employed and comprises on average at least about 80% of the hydrogen atoms at the bis - allylic sites replaced by deuterium atoms. In one embodiment, the deuterated arachidonic acid or ester thereof comprises on average at least about 80% of the hydrogen atoms at the bis-allylic sites replaced by deuterium atoms and no more than about 35% on average of the hydrogen atoms at the mono-allylic sites replaced by deuterium atoms.
[0071] In one embodiment, such administration comprises the use of a dosing regimen that includes two dosing components. The first dosing component comprises a primer or loading dose of the deuterated arachidonic acid or an ester thereof. The second dosing component comprises a maintenance dose of deuterated arachidonic acid or an ester thereof, wherein the amount of the deuterated arachidonic acid or an ester thereof in said second dosing component is less than that in the first dosing component.
[0072] In an embodiment, the loading dose comprises at least about 0.05 grams of deuterated arachidonic acid or an ester thereof per day. In an embodiment, the loading dose for the deuterated arachidonic acid or ester thereof ranges from about 0.05 grams to about 2 grams per day, administered on a periodic basis as described herein. In general, the D4-arachidonic acid or esters thereof will require less of a loading dose than the D2-arachidonic acid or esters thereof and the D6-arachidonic acid or ester thereof require less of a loading dose than the D6-arachidonic acid or esters thereof. Without being limited to any theory, the ability to reduce the amount of deuterated arachidonic acid or esters thereof with higher levels of deuteration is due to the greater extent of protection against lipid peroxidation in vivo. accorded by the increased levels of deuteration. Still further, the dosing of about 0.0.5 grams to about 2 grams per day is measured by the total amount of deuterated arachidonic acid discounting for impurities and the ester portion of the arachidonic acid ester if an ester prodrug is employed. When so employed, the ester group is readily deacylated in the gastrointestinal track. In embodiments, the loading dose is from about 0.05 grams to about 1.5 grams per day. In embodiments, the loading dose is from about 0. lO grams to about 1.5 grams per day. In embodiments, the loading dose is from about 0. 10 grams to about 1 .25 grams per day. In embodiments, the loading dose is from about 0. 10 grams to about 1 gram per day. In embodiments, the loading dose is from about 0.10 grams to about 0.5 grams per
day . The loading dose may be any value or subrange within the recited ranges, including endpoints.
[0073] As to the primer dose, the amount of deuterated arachidonic acid or an ester thereof employed is designed to provide rapid onset of therapy. Such therapy is measured by a reduction in the disease progression of neurodegenerative diseases as described below. In an embodiment, the primer dose takes into account the various complicating factors, such as the amount of PUFAs consumed by the patient in a given day as well as the general turnover rate of lipids (half-life) in the patient’s neurons.
[0074] Regarding this last point, the lipid components of neurons are not static but, rather, are exchanged overtime and have a finite half-life in the body. In general, only a fraction of the lipids components in the lipids are replaced each day. In the case of neurons, these cells are rich in arachidonic acid. The turnover of arachidonic acid in these membranes occurs from a stable pool of lipids comprising arachidonic acid in the spinal fluid. In turn, this stable pool is replaced and replenished overtime by arachidonic acid included in the newly consumed lipids by the patient as part of the patient’s diet as well as by biosynthesis of arachidonic acid from linoleic acid. In embodiments, the maintenance dose of deuterated arachidonic acid or ester thereof is titrated such that the amount of deuterated arachidonic acid administered matches the rate of secretion from the body.
[0075] The choice of a dosing of deuterated arachidonic acid or an ester thereof as described herein allows for the rapid accumulation of a sufficient amount of deuterated arachidonic acid in the body to achieve early onset to therapeutic concentrations in vivo. When so achieved, the data in the Examples establish that there is a significant reduction in the rate of disease progression.
[0076] In embodiments, the loading dose of the dosing regimen described herein includes sufficient amounts of deuterated arachidonic acid that are absorbed into the patient. Once maximized, the resulting deuterated arachidonic acid accumulates in the body and reaches a therapeutic concentration in the patient within about 10 to 45 days after the start of therapy. During this process, deuterated arachidonic acid is systemically absorbed into the cells of the body including neurons. In embodiments, the loading dose is administered for about 10 to about 50 days. In embodiments, the loading dose is administered for about 15 to about 50 days. In embodiments, the loading dose is administered for about 20 to about 50 days. In
embodiments, the loading dose is administered for about 10 to about 45 days. In embodiments, the loading dose is administered for about 15 to about 45 days. In embodiments, the loading dose is administered for about 20 to about 30 days. The length of time may be any value or subrange within the recited ranges, including endpoints.
[0077] In embodiments, the loading dose is administered at least 5 days per week. In embodiments, the loading dose is administered at least 7 days per week. In embodiments, the loading dose is administered at least once per week. In embodiments, the loading dose is administered at least once per month.
[0078] In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 65% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 60% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 55% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 50% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 45% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 40% of the loading dose.
[0079] In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 35% of the loading dose. In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 30% of the loading dose.
[0080] In embodiments, the maintenance dose is administered at least 5 days per week. In embodiments, the maintenance dose is administered at least 7 days per week. In embodiments, the maintenance dose is administered at least once per week. In embodiments, the maintenance dose is administered at least once per month.
[0081] As is apparent, it is not practical to ascertain the concentration of deuterated arachidonic acid in a patient’s neurons. This requires that such concentrations be ascertained indirectly by a reporter cell such as a red blood cell, a skin cell, etc. In the case of 13, 13 -D2- arachidonic acid, at the time a therapeutic result in ascertained, red blood cells are obtained from the patient, the amount of 13, 13-D2-arachidonic acid contained in said red blood cells
based on the total amount of arachidonic acid present, including 13,13 -D2 -arachidonic acid is measured. When so evaluated, a concentration of at least about 3% and preferably at least about 5%, and more preferably, at least about 8% of 13,13-D2-arachidonic acid when tested at one (1) month after the start of therapy was found to represent a threshold amount required for therapeutic results in the neurons. When so administered, there is a significant reduction in the progression rate of the neuro degenerative disease being treated.
[0082] The methods described herein are also based, in part, on the discovery that the dosing regimen set forth herein provides for rapid uptake or accumulation of deuterated arachidonic acid in the lipid membrane of neurons which then stabilizes these membranes against LPO. As a result, there is a substantial reduction in the progression of the neurodegenerative disease. This is believed to be due to the replacement of hydrogen atoms with deuterium atoms in the deuterated arachidonic acid, rendering the deuterated arachidonic acid significantly more stable to ROS than the hydrogen atoms. As above, this stability manifests itself in reducing the cascade of lipid auto -oxidation and, hence, limiting the rate of disease progression.
[0083] In the specific instance of ALS, the reduction in the progression of this disease can be readily calculated by using the known and established rate functional decline measured by the R — ALS Functional Rating Scale-revised after commencement of drug therapy as compared to the rate of decline prior to drug therapy (natural history of decline). As the rate of decline is not perceptible on a day-to-day basis, the functional decline is typically measured monthly and is evaluated over a period of time, such as every 1 to 24 months, such as every 3 months, every 6 months, or annually. The period of time may be any value or subrange within the recited ranges, including endpoints.
[0084] As set forth in the examples below, the rate of functional decline is predicated on measuring an individual’s, or a cohort’s, average for the natural history of disease progression. Next, the individual or cohort average for the functional decline is determined at a period of time such as at 3, 6 or 12 months after initiation of therapy. The rate of decline based on the average of the natural history of the cohort is set as the denominator. The numerator is set as the delta between the rate of the natural history of disease progression and the rate of functional decline after a set period of treatment per this invention . The resulting fraction is the multiplied by 100 to give a percent change. The following exemplifies this analysis.
[0085] Cohort A has an average natural history rate of decline in functionality of 28 annualized for a one (1 ) year period. Six (6) months after initiation of treatment per this invention, Cohort A an annualized average rate of decline in functionality has dropped to 14. This provides a delta of 14 degrees. So, using 14 as the numerator and 28 as the denominator and then multiplying result by 100, one obtains a reduction in the annualized rate of decline of 50 percent.
[0086] In general, the methods of this invention provide for an average percent change in reduction in functionality for a cohort of at least 30% and, more preferably, at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%. In embodiments, the change in reduction of functionality is measured over a time period, for example 1 month to 24 months, e.g., at 3 months, at 6 months, or annually. The rate of decline can be measured over any time period intermediate between 3 months and 1 year.
[0087] As noted above, the dosing regimen also addresses the challenge of providing for a dosing regimen that allows for rapid onset to therapeutic concentrations of deuterated arachidonic acid to quickly reduce the rate of disease progression in the patient so as to minimize the additional loss of functionality. It is to be understood that reducing the rate of disease progression correlates to longer periods of retained functionality in the patient and likely a longer lifespan. Accordingly, the faster one reaches such a reduced rate, the better off it is for the patient.
[0088] In one embodiment, the methods described herein address this challenge by employing a dosing regimen which delivers deuterated arachidonic acid in amounts sufficient to provide for a therapeutic amount to the neurons. When so incorporated, the deuterated arachidonic acid reduces the degree of LPO which, in turn, effectively limits progression of ALS provided it is administered in appropriate amounts.
Combinations
[0089] The therapy provided herein can be combined with other treatments used with neurodegenerative diseases provided that such therapy . In one embodiment, deuterated linoleic acid or an ester thereof (including 11, 1 l-D2-linoleic acid ethyl ester) can be used to supplement or replace deuterated arachidonic acid or an ester thereof in the loading dose or the maintenance dose provided that replacement is limited to either the loading dose or the
replacement dose but not both. This is due to the fact that a portion of 11, 11 -D2-linoleic acid is bioconverted (e.g., convertedwithin the body) to 13, 13-D2-arachidonic acid. The total amount so converted is a fraction of the amount of 11,1 l-D2-linoleic acid or ester thereof administered. This fractional conversion allows the clinician to titrate the amount of 13,13- D2-arachidonic acid downward by administering 11,11 -D2-linoleic acid or ester thereof. This is particularly the case for the maintenance dose where minimal amounts of 13, 13 -D2- arachidonic acid may be required as the literature recognizes that the amount of biogenerated arachidonic acid is low. See, e.g., Tallima, et al., J. Adv. Res., 11 :33 -41 (2018). As to 11,11- D2-linoleic acid or ester thereof, the term “ester thereof’ refers to the same term used with regard to deuterated arachidonic acid or esters thereof.
[0090] In another embodiment, a combination therapy can employ a drug that operates via an orthogonal mechanism of action relativeto inhibition of lipid auto -oxidation. Suitable drugs for use in combination include, but not limited to, antioxidants such as edaravone, idebenone, mitoquinone, mitoquinol, vitamin C, or vitamin E provided that none of these anti-oxidants that are directed to inhibiting lipid auto-oxidation, riluzole which preferentially blocks TTX- sensitive sodium channels, conventional pain relief mediations, and the like.
Pharmaceutical Compositions
[0091] The specific dosing of deuterated arachidonic acid or an ester thereof is accomplished by any number of the accepted modes of administration. As noted above, the actual amount of the drug used in a daily or periodic dose per the methods of this invention, i.e., the active ingredient, is described in detail above. The drug can be administered at least once a day, preferably once or twice or three times a day.
[0092] This invention is not limited to any particular composition or pharmaceutical carrier, as such may vary. In general, compounds of this invention will be administered as pharmaceutical compositions by any of a number of known routes of administration.
However, orally delivery is preferred typically using tablets, pills, capsules, and the like. The particular form used for oral delivery is not critical but due to the large amount of drug to be administered, a daily or periodic unit dose is preferably divided into subunits having a number of tablets, pills, capsules, and the like. In one particularly preferred embodiment, each subunit of the daily or periodic unit dose contains about 1 gram of the drug. So, a daily or periodic unit dose of 9 grams of the drug is preferably provided as 9 sub -unit doses containing about 1 gram of the drug. Preferably, the unit dose is taken in one, two or three
settings but, if patient compliance is enhanced by taking the daily or periodic unit dose over 2 or 3 settings per day, such is also acceptable.
[0093] Pharmaceutical dosage forms of a compound as disclosed herein may be manufactured by any of the methods well-known in the art, such as, by conventional mixing, tableting, encapsulating, and the like. The compositions as disclosed herein can include one or more physiologically acceptable inactive ingredients that facilitate processing of active molecules into preparations for pharmaceutical use.
[0094] The compositions can comprise the drug in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the claimed compounds. Such excipient may be any solid, liquid, or semi-solid that is generally available to one of skill in the art.
[0095] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Other suitable pharmaceutical excipients and their formulations are described in Remington ’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
[0096] The compositions as disclosed herein may, if desired, be presentedin a pack or dispenser device each containing a daily or periodic unit dosage containing the drug in the required number of subunits. Such a pack or device may, for example, comprise metal or plastic foil, such as a blister pack, a vial, or any other type of containment. The pack or dispenser device maybe accompanied by instructions for administration including, for example, instructions to take all of the subunits constituting the daily or periodic dose contained therein.
[0097] The amount of the drug in a formulation can vary depending on the number of subunits required for the daily or periodic dose of the drug. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 10 to 99 weight percent of the drug based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 50 to 99 weight percent.
[0098] In preferred embodiment, the drug is encapsulated inside a capsule without the need for any pharmaceutical excipients such as stabilizers, antioxidants, colorants, etc. This minimizes the number of capsules required per day by maximizing the volume of drug in each capsule.
EXAMPLES
[0099] This invention is further understood by reference to the following examples, which are intended to be purely exemplary of this invention. This invention is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of this invention only. Any methods that are functionally equivalent are within the scope of this invention. Various modifications of this invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the appended claims. In these examples, the following terms are used herein and have the following meanings. If not defined, the abbreviation has its conventional medical meaning.
D2-AA 13,13 -D2-Arachidonic Acid
AA Arachidonic Acid
ALSFRS-R Revised ALS Functional Rating Scale
CNS Central Nervous System
CSF Cerebral Spinal Fluid
D2-LA 11,11 -D2-Linoleic Acid (aka “drug”)
LA Linoleic Acid
LPO Lipid peroxidation
PK Ph arm ac okin eti c s
RBC Red Blood Cells
SAE Serious Adverse Events
Example 1 - Determination of AA Concentrations in RBCs and Spinal Fluid / Neurons in a Single Patient
[0100] This example determines the relative concentration of D2-AA in the CSF and in RBCs in order to determine a correlation between these two concentrations. Specifically, a patient was continuously provided with a daily dose of 9 grams of D2-LA ethyl ester (which is 8.64 grams of active discounting for impurities and removal of the ethyl ester) over about a six-month period. Periodic samples of blood and SF were taken and the concentration of both D2-LA and D-2AA in both the RBCs and the SF were measured. In all cases, the D2- AA was obtained by deacylation of the ethyl ester of linoleic acid in the gastrointestinal tract followed by conversion of D2-LA in vivo to D2-AA.
Table 1
The results found in Table 1 showthatthe concentration of D2-AA in the cerebral spinal fluid is already 8% based on the amount of arachidonic acid + deuterated arachidonic acid.
[0101] Next, Table 2 shows that the concentration of D2 -LA and D2-AAin the RBCs at 3 months and 6 months for the same patient.
[0102] Note here thatthe concentration of D2-AAin RBC’s at 3 months is less than that at 6 months evidencing the incremental increase in D2-AA over time. Moreover, there is an apparent change in the ratio of D2-LA to D2-AA at 2.9 : 1 at 3 months which changes to 2.1 : 1 at 6 months. In one embodiment, the ratio of D2-LA to D2-AA in RBCs at 3 and 6 months is represented as 2.5 :1 +/- 0.4 which corresponds favorably to that found in Table 1 .
[0103] Since the amount of D2-AA is increasing overtime in an incremental fashion based on the bioconversion of D2-LA, one can assume a fairly linear rate of increase. This is shown in FIG. 1, where the solid line is set by the concentrations of D2-AA at 3 months and 6 months and then extrapolated backto start of therapy (0 months). The value for the D2 -AA in RBC’s at 1 month is estimated from this relationship. The amount shown for 1 month in the CSF is also provided (open circle).
[0104] Based on the above, one can see that the data to date suggests that the amount D2-AA at 1 month in RBCs would be about 3 percent as compared to 8% for the amount of D2 -AA in the SF. Accordingly, this data suggests that the concentration the body shunts more of the AA (including D2-AA) into the CSF (and hence the neurons) as compared to RBCs and likely other reporter cells.
Example 2 - Determination of AA Concentrations in RBCs and Spinal Fluid / Neurons in a Cohort of 14 Patients
[0105] In this example, children suffering from INAD were treated with a daily dose of 3.9 grams of D2-LA ethyl ester followed by 2.9 grams of D2-LA ethyl ester. Given the age and weight of these children, such is assumed to be substantially equivalent to a loading dose of from about 7 and about 12 grams per day for an adult patient for an adult patient and a maintenance dose which is less than the loading dose again for an adult patient.
[0106] This example also determines the concentration of D2-AA in RBCs. Specifically, a cohort of 14 children was provided with a daily dose of 3.9 grams of D2-LA ethyl ester for 1 month followed by 2.9 grams ofD2-LA ethyl ester for the remaining six -month period. Blood samples were taken at 3 months for all but 1 child and at 6 months for all children. The concentration of D2-AA in RBCs was measured. In all cases, the D2-AA was obtained by deacylation of the ethyl ester of linoleic acid in the gastrointestinal tract followed by bioconversion of D2-LA in vivo to D2-AA.
[0107] At 3 months, the average concentration of D2-AA in the RBCs was determined to be 12% (6.8% low and 16.8% high). At 6 months, the average concentration ofD2-AA in the RBCs was determined to be 16.7% (12.0% low and 26.1% high). Agraph depicting these results is provided as FIG. 2. The line shows a linear relationship of D2-AA accumulation in the body. Included in this graph is the 1 -month data for D2-AA in the spinal fluid as found in Example 1.
[0108] As can be seen, the graphs in FIGs. 1 and 2 are substantially the same, strongly suggesting that the dosing of D2-LA to the adult patient in Example 1 and to the children in Example 2 maximized the bioconversion of D2-LA to D2-AA. This data further suggests that once maximized, the amounts of D2-AA generated overtime are reproducible.
COMPARATIVE EXAMPLE A - The Use of Prodrug of 13,13-Arachidonic Acid
[0109] Patients suffering from ALS were treated with D2-LA over a period of time. The patients were given different dosing amounts of D2-LA and for different dosing periods but did notfollowthe dosing protocol described in US SerialNo. 17/ 391,909, whichis incorporated herein by reference in its entirety . Some patients were provided 2 grams of 11,11 -D-2 LA per day as opposed to the loading dose of 9 grams per day .
[0110] Functional scores for each of the patients (ALSFRS-R results) at the end of therapy were compared to the natural history scores at the start of therapy. Based on this comparison, the rate of decline changed from an annualized rate of -14.2+/- 4.4 peryear pre-treatmentto - 7.6 +/- 1.4 during treatment or a 46% reduction (p=0.07, pairedt-test for within-subject change in slope). When calculated, the amount of D2-AA in the patients’ RBCs averaged at about 3% based on the total amount of AA and D2-AA present evidencing that such a concentration provided for therapeutic results.
[0111] As D2-LA acts as a pro-drug of D2-AA, the 3% amount of D2-AA in red blood cells shown to be therapeutic would be independent of whether it is delivered by in vivo conversion ofD2-LA or by direct administration of D2-AA.
Example 3 - Benefits of the Dosing Protocol Using D2-LA
[0112] This example illustrates the reduction in the rate of disease progression in patients with ALS treated by the dosing methods described herein. Specifically, a cohort of 3 patients was placed on a dosing regimen consisting of a first dosing component (primer dose) of about 9 grams of D2-LA ethyl ester daily for a period of at least 30 days and then all three patients were transitioned to a second dosing component (maintenance dose) of 5 grams of D2-LA ethyl ester.
[0113] The functionality of each of the patients was evaluated periodically using the ALSFRS-R protocol. The patients continued on the dosing regimen for a period of 6 months (patient A) or 1 year (patient B) or for 9 months (patient C). Patient C died at the end of 9 months and his death was attributed to factors other than ALS cardiomyopathy. Before initiation of therapy, the natural history of each patient in the cohort was determined and an average annual rate of functional decline was measured at 21 .
[0114] The annualized progression of the disease, as measured by an average annual rate of functional decline for all three patients starting at the time that dosing began and terminating at the end of the dosing regimen and then annualized as described above, was measured as 2.1. Using the formula described above, one obtains the following:
(21 -2.1 )/21 x 100 = 90% annualized average reduction in the rate of disease progression.
[0115] The specific values for each of the three members of the cohort are as follows in Table 5 :
Table 5
Patient NH Rate of Decline Functional Rate Decline During Therapy
A -16 -3
B -31 -2
C -16 -1.3
NH = Natural History
[0116] These results substantiate a very significant rate of reduction in the disease progression using the dosing regimen as per this invention. These results also substantiate that transitioning patients from a primer dose to a maintenance dose maintains the beneficial stabilization in the rate of decline.
[0117] In comparison, patients treated with 9 gm of D2-LA per day for about 1 month followed by 5 gm of D2-LA per day thereafter evidence about a 90% reduction in the rate of disease progression. Compared to the 46% rate of reduction in the loss of functionality. This establishes that the dosing regimen described herein provides for a significant benefit to patients in their reduction in the rate of disease progression.
Example 4 - Survival of Murine Fibroblast Cells in the Presence ofErastin
[0118] This example was designed to measure the relative protective activity of 13,13 -D2- arachidonic acid as compared to 7,7,10, 10,13,13 -D6-arachidonic acid in protecting murine fibroblasts from lipid peroxidation mediated cell death. In this example, two different pools of cells were each seeded in 48-well plates and treated with 50 micromolar of erastin. Cells were incubated with either 13,13-D2-arachidonic acid or 7,7, 10,10,13, 13 -D6-arachidonic acid.
[0119] Afterwards, cell viability was measured by plate dilution assay to distinguish between cells that are alive and those that are dead on a Petri dish . The results are as follows:
[0120] These results evidence that 7, 7, 10, 10,13, 13 -D6-arachidonic acid provides approximately twice the level of protection against LPO induced cell death as compared to 13,13 -D2-arachidonic acid.
DOSING BASED ON THE EXAMPLES
[0121] The amount of LA bioconverted to AA is deemed to be in the range of from about 5% to about 30% of the LA consumed. The exact conversion rate depends on factors such as the amount of PUFAs consumed, the amount of AA present in the body coupled with feedback loops, any rate limiting enzymatic steps, and the underlying metabolism of the patient. Therefore, if 2 grams of D2-LA successfully achieves about a 3.0 percent (a therapeutic level) of D-2AA in red blood cells as per Comparative Example A above, and if 15% of the D2-LA (approximately half of 5 to 30 percent) is converted to D2-AA, then one can deduce that:
A. At a 15% conversion rate, the 2 grams of D2-LA would generate about 0.3 grams of D2-AAby bioconversion.
B. At a 30% conversion rate, the 2 grams of D2 -LA would generate about 0.6 grams of D2-AAby bioconversion.
[0122] Still further, Example 4 illustrates thatD6-AA is about2 times more active than D2- AA. So, when using D6-AA, one can deduce that it will require slightly less than half as much as D2-AA. So, at a low end, the 0.3 grams of D2-AA would translate into about 0. 15 grams of D6-AA, or perhaps less. As to the loading dose of D4-AA, it will be intermediate between that for D2-AA and D6-AA.
[0123] Still further, to achieve the benefits of Example 3 of a significantly reduced rate of loss of functionality, a dose of 9 grams per day ofD2-LA would be required. At a 15% conversion rate, such would translate to 1 .45 grams per day of D2-AA. For D6-AA, a reduction by 50% would provide for about 0.75 grams per day.
[0124] With the above factors considered, in embodiments, the loading dose of deuterated arachidonic acid or ester thereof is expected to range from about 0.01 grams to about 2 grams per day. In a preferred embodiment, dosing is from about 0.05 grams to about 1.5 grams per day. In embodiments, the loading dose is from about 0.10 grams to about 1.5 grams per day. In embodiments, the loading dose is from about 0.10 grams to about 1 .25 grams per day. In
embodiments, the loading dose is from about 0.10 grams to about 1 gram per day. In embodiments, the loading dose is from about 0.10 grams to about 0.5 grams per day, with preferred dosing ranges of from about 0.1 to about 1.5 grams of deuterated arachidonic acid. Other preferred ranges are provided above.
[0125] In embodiments, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than about 65% of the loading dose. In one embodiment, the maintenance dose of deuterated arachidonic acid or an ester thereof comprises no more than 55% of the loading dose. In one embodiment, the maintenance dose of deuterated arachidonic acid or an ester thereof is calibrated to be an amount of deuterated arachidonic acid or an ester thereof sufficient to replace the amount of deuterated arachidonic acid eliminated from the body.
Claims
1. A method for reducing disease progression of a neurodegenerative disease treatable with a deuterated arachidonic acid in an adult patient, the method comprising: administering a deuterated arachidonic acid or an ester thereof to the patient with a dosing regimen that comprises a primer dose and a maintenance dose, thereby reducing said disease progression in said patient, wherein: a) said primer dose comprises periodic administration of a deuterated arachidonic acid or an esterthereof, wherein said primer dose is continued for about 30 daysto about 45 days to rapidly achieve a therapeutic concentration of said deuterated arachidonic acid /// vivo, and b) subsequent to the completion of the primer dose, periodically administering said maintenance dose of no more than about 65% of the loading dose of deuterated arachidonic acid or an ester thereof per day thereof to maintain said therapeutic concentration of said deuterated arachidonic acid in vivo, such that the rate of disease progression is reduced, wherein the neurodegenerative disease is mediated at least in part by lipid peroxidation of polyunsaturated fatty acids in neurons of the patient.
2. The method of claim 1 , wherein said disease is amyotrophic lateral sclerosis, Huntington’s Disease, progressive supernuclear palsy (PSP), Friedreich’s ataxia, APO-e4 Alzheimer’s Disease, corticobasal disorder (CBD), frontotemporal dementia (FTD), nonfluent variant primary progressive aphasia (nfvPPA), other tauopathies, or late onset Tay- Sachs.
3. The method of claim 1 or 2, wherein said periodic administration of the loading dose comprises administration of at least about 0.05 grams of deuterated arachidonic acid or an esterthereof per day for at least 5 days per week.
4. The method of claim 1 or 2, wherein said deuterated arachidonic acid or an esterthereof comprises a Ci-C6 alkyl ester of a deuterated arachidonic acid.
5. The method of any one of claims 1 to 4, wherein the maintenance dose comprises no more than 55% of the loading dose.
6. The method of claim 5, wherein the maintenance dose comprises no more than 35% of the loading dose and is administered at least once a week.
7. The method of claim 6, wherein the maintenance dose is administered at least once a month.
- 32 -
8. The method of any one of claims 1 to 7, which further comprises restricting the patient’s consumption of excessive dietary polyunsaturated fatty acids during administration of said primer and said maintenance doses.
9. The method of any one of claims 1 to 8, wherein said primer dose and/or said maintenance dose is provided in 1 , 2 or 3 administrations during a single day.
10. The method of any one of claims 1 to 9, wherein said neuro degenerative disease is amyotrophic lateral sclerosis, Huntington’s Disease, progressive supernuclear palsy (PSP), Friedreich’s ataxia, or APO-e4 Alzheimer’s Disease.
11 . The method of claim 10, wherein said neuro degenerative disease is APO e-4 variant of Alzheimer’s Disease.
12. The method of claim 10, wherein said neurodegenerative disease is PSP.
13. The method of claim 10, wherein said neurodegenerative disease is Huntington’s Disease.
14. The method of claim 10, wherein said neurodegenerative disease is amyotrophic lateral sclerosis.
15. The method of claim 10, wherein said neurodegenerative disease is Friedreich’s ataxia.
16. A kit of parts comprising a set of capsules each comprising a partial loading dose of a deuterated arachidonic acid or an ester thereof, such that two or more of said capsules comprise a complete loading dose per day.
17. A kit of parts comprising a set of capsules each comprising a partial loading dose of a deuterated arachidonic acid or an ester thereof, such that nine of said capsules comprise a complete loading dose per day.
18. A kit of parts comprising a set of capsules each comprising a partial maintenance dose of a deuterated arachidonic acid or an ester thereof, such that two or more of said capsules comprise a complete maintenance dose per day.
19. A kit of parts comprising a set of capsules each comprising a partial maintenance dose of a deuterated arachidonic acid or an ester thereof, such that five of said capsules comprise a complete maintenance dose per day.
- 33 -
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/408,285 | 2021-08-20 | ||
US17/408,285 US11510889B2 (en) | 2021-02-05 | 2021-08-20 | Methods for inhibiting the progression of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023023397A1 true WO2023023397A1 (en) | 2023-02-23 |
Family
ID=85241129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/041062 WO2023023397A1 (en) | 2021-08-20 | 2022-08-22 | Methods for inhibiting the progression of neurodegenerative diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023023397A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023158641A1 (en) * | 2022-02-15 | 2023-08-24 | Retrotope, Inc. | Synergistic combination therapy for treating als |
WO2023220058A1 (en) * | 2022-05-09 | 2023-11-16 | Retrotope, Inc. | Therapeutic methods for treating als |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2798053A (en) * | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
US3755560A (en) * | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US20020198177A1 (en) * | 2001-05-30 | 2002-12-26 | Horrobin David Frederick | Coenzyme Q and EPA |
US20090181367A1 (en) * | 2002-07-05 | 2009-07-16 | Helene Cote | Diagnosis of sepsis using mitochondrial nucleic acid assays |
-
2022
- 2022-08-22 WO PCT/US2022/041062 patent/WO2023023397A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2798053A (en) * | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
US3755560A (en) * | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US20020198177A1 (en) * | 2001-05-30 | 2002-12-26 | Horrobin David Frederick | Coenzyme Q and EPA |
US20090181367A1 (en) * | 2002-07-05 | 2009-07-16 | Helene Cote | Diagnosis of sepsis using mitochondrial nucleic acid assays |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023158641A1 (en) * | 2022-02-15 | 2023-08-24 | Retrotope, Inc. | Synergistic combination therapy for treating als |
WO2023220058A1 (en) * | 2022-05-09 | 2023-11-16 | Retrotope, Inc. | Therapeutic methods for treating als |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5780489A (en) | Method for treating amyotrophic lateral sclerosis | |
WO2023023397A1 (en) | Methods for inhibiting the progression of neurodegenerative diseases | |
US5834032A (en) | Compositions and methods for treating diabetes | |
US20230255917A1 (en) | Methods of treating amyotrophic lateral sclerosis | |
US11351143B1 (en) | Methods of treating amyotrophic lateral sclerosis | |
EP1937286B1 (en) | Compositions comprising dimethyl sulfoxide (dmso) | |
WO2022170134A2 (en) | Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof | |
US20230165824A1 (en) | METHODS, SYSTEMS AND COMPOSITIONS FOR INHIBITION OF CELLULAR DYSFUNCTION AND CELL DEATH WITH DEUTERATED PUFAs | |
WO2012022468A2 (en) | Benzoquinone derivatives as modulators of mitchondrial function | |
JP2010507572A (en) | Combination therapy | |
US11510889B2 (en) | Methods for inhibiting the progression of neurodegenerative diseases | |
US20240115535A1 (en) | Methods for Inhibiting the Progression of Neurodegenerative Diseases | |
US20180318243A1 (en) | Use of lithium benzoate for treating central nervous system disorders | |
EP4373479A1 (en) | Methods for inhibiting the progression of oxidative retinal diseases | |
US20220249442A1 (en) | Synergistic combination therapy for treating als | |
US20230100267A1 (en) | Inhibition of cellular dysfunction and cell death with deuterated polyunsaturated fatty acids | |
US20240091188A1 (en) | Dosing Protocols for Administering Deuterated Arachidonic Acid or a Prodrug Thereof | |
CN118201607A (en) | Methods, systems, and compositions for inhibiting cell dysfunction and cell death using deuterated PUFAs | |
WO2023158641A1 (en) | Synergistic combination therapy for treating als | |
WO2008021996A2 (en) | Nutritional supplement for increased energy and stamina | |
WO2023192530A1 (en) | Prophylactic methods for treating als | |
EA045710B1 (en) | USE OF COMPOSITIONS CONTAINING AMINO ACIDS FOR PREVENTION AND TREATMENT OF CARDIOTOXICITY INDUCED BY CHEMOTHERAPEUTIC AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22859261 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |